Childhood exposure to non-persistent endocrine disruptors, glucocorticosteroids, and neurodevelopment: A study based on the parametric g-formula

# Abstract

Epidemiological evidence suggests that exposure to endocrine disrupting chemicals (EDCs) may be linked to perturbation of the hypothalamic-pituitary-adrenocortical (HPA) axis, which has a major role in brain development. We aimed to evaluate the effects of childhood exposure to organophosphate pesticides, phenols, and phthalate metabolites, on urinary glucocorticosteroids and inattention measures in children. We used data from the Human Early-Life Exposome (HELIX) cohort including 1,297 children aged 6-11. We used the parametric g-formula and marginal contrasts (MCs) to estimate effects between EDCs, glucocorticosteroids, and hit reaction time standard error (HRT-SE), a measure of efficiency from the Attention Network Test (ANT), and tested for possible effect modification by sex. We observed positive MCs for exposure increases from the 10th to the 90th percentile for methyl-paraben (marginal contrast (MC) and confidence interval (CI): 0.04 (0.01, 0.07)), and the phthalate metabolites oxo-MiNP (MC and CI: 0.02 (0, 0.04)), oh-MiNP (MC and CI: 0.04 (0, 0.08)), and MEHP (MC and CI: 0.04 (0.01, 0.06)), on HRT-SE. Several EDCs were also associated with positive MCs of cortisone, cortisol, and corticosterone production. Increased levels of the glucocorticosteroids had no effect on HRT-SE, although we found possible effect modification by sex for cortisone and corticosterone production. Our results suggest that multiple EDCs might interfere with inattentiveness outcomes in children and with the homeostasis of the HPA axis. Further research is necessary to determine whether this can have a clinically significant impact on childhood neurodevelopment.

* Authorship must follow the ICMJE’s criteria. Author names should be listed in ScholarOne and author contributions should be detailed in the cover letter (“Author A…”). Neither names nor contributions should appear in the blinded manuscript. Do not include conflicts of interest.
* The length of the abstract must be less or equal than 200 words, and should be unstructured, stating the research questions, the methods used, and the results and conclusions of the research.
* The length must be <4,000 words, excluding abstract, references, tables, figure captions, acknowledgments, and Supplementary Material.
* Submission: SER members receive a 10% discount on the fees per page. This should be requested in the cover letter. Also 20% discount for Open Access charges. If uploading a single file (document, tables, figures, SM), designate the file as “Main document - anonymous”.

The prevalence of several neurodevelopmental disorders has increased in the pediatric population ([1](#ref-GrandjeanLandrigan:2014)), and multiple environmental pollutants may play a role in the increased rates of these disorders ([2](#Xd81cf38a3b251ec377f8aa13b097ea9d0c190e3)). endocrine disrupting chemicals (EDCs), ubiquitous chemicals present in many every-day products and diet, are capable of interfering with the endocrine system, and have shown associations with childhood neurodevelopment and behavior ([3](#ref-BouchardBellingerWright:2010)–[17](#ref-VilmandBeckBilenberg:2023)). Although both pregnancy and early childhood are crucial stages of (neuro)development, most of the available literature is focused on the effects of prenatal exposure to EDCs on child neurodevelopment ([2](#Xd81cf38a3b251ec377f8aa13b097ea9d0c190e3)).

One group of EDCs that may have a deleterious effect on neurodevelopment is the organophosphate pesticides (OP pesticides), although the few studies assessing exposure during childhood and through the use of biomarkers suffered from a series of limitations, including a small sample size and few organophosphate pesticide (OP pesticide) metabolites measured ([2](#Xd81cf38a3b251ec377f8aa13b097ea9d0c190e3)). Exposure to phthalates and their metabolites during childhood and early adolescence has been associated to several adverse neurodevelopmental outcomes, but these studies were limited to few phthalate metabolites and small study populations ([2](#Xd81cf38a3b251ec377f8aa13b097ea9d0c190e3)). The effects of exposure to bisphenol A (BPA) during childhood on cognitive functions are still unclear ([2](#Xd81cf38a3b251ec377f8aa13b097ea9d0c190e3)).

Moreover, little is known about the biological mechanisms of action ([2](#Xd81cf38a3b251ec377f8aa13b097ea9d0c190e3)). There is some toxicological evidence, however, that exposure to certain EDCs, specifically phthalates, might interfere with the hypothalamic-pituitary-adrenocortical (HPA) axis and might interact with the glucocorticoid receptor ([18](#ref-KimLeeMoon:2018)–[20](#ref-SearsLiuLanphear:2023)). The HPA axis, which can be activated by stress, is responsible for the production of glucocorticosteroids. The brain, and its proper functioning, is a potential target, due to the presence of receptors for these hormones ([19](#ref-SunLiJin:2018),[21](#ref-LupienMcEwenGunnar:2009)). Glucocorticosteroids are necessary for brain maturation, although their under- or over-production might interfere with its normal development and ultimately lead to long-term impaired functioning ([20](#ref-SearsLiuLanphear:2023),[21](#ref-LupienMcEwenGunnar:2009)).

Taken together, these results suggest that the negative influence of exposure to certain EDCs on neurodevelopmental outcomes, might be mediated, at least partially, by disruption of the HPA axis’ homeostasis. In the present study, we thus estimated associations between 1) non-persistent EDCs and attention, 2) non-persistent EDCs and glucocorticosteroids, and 3) glucocorticosteroids and attention, using the parametric g-formula and marginal contrasts (MCs), in children of a large cohort in Europe.

# Methods

## Study population and design

The Human Early-Life Exposome (HELIX) project aims to characterize early-life exposures and their potential association with endogenous biomarkers and health outcomes ([22](#ref-VrijheidSlamaRobinson:2014)). It consists of six existing population-based birth cohort studies across Europe: BiB (Born in Bradford, UK) ([23](#ref-WrightSmallRaynor:2013)), EDEN (Study of determinants of pre- and postnatal developmental, France) ([24](#ref-HeudeForhanSlama:2016)), INMA (Environment and Childhood, Spain) ([25](#ref-GuxensBallesterEspada:2012)), KANC (Kaunas Cohort, Lithuania) ([26](#Xd30c40380c9e99bac70b7fa3b0ada5ae8dec3e4)), MoBa (The Norwegian Mother and Child Cohort Study, Norway) ([27](#ref-MagnusIrgensHaug:2006)), and Rhea (Mother–Child Cohort in Crete, Greece) ([28](#ref-ChatziPlanaDaraki:2009)). The HELIX subcohort of 1,301 mother-child pairs was fully characterized for the external and internal exposome, including exposure and omics biomarkers during childhood ([29](#ref-MaitreBontCasas:2018)). Eligibility criteria for inclusion in the HELIX subcohort included: a) age 6-11 years, with a preference for 7-9 years; b) availability of sufficient stored pregnancy blood and urine samples; c) availability of complete address history from first to last follow-up; d) no serious health problems, which might affect the results of the clinical testing. Ethical permission was obtained from the relevant authorities in the corresponding country.

## Variables

### Endocrine disrupting chemicals

Children were assessed between December 2013 and February 2016, and assessments included neurological testing and urine collection. Urine samples of the night before and the first morning void on the day of the visit were combined to provide a more reliable exposure assessment. Non-persistent EDCs assessed in the urine samples included phthalate metabolites, phenols, and organophosphate (OP) pesticide metabolites. A list of the environmental chemicals determined in urine samples and used for the present study is given in [Table S5](#supptbl-info-chems). Briefly, we analyzed a total of 7 phenols (bisphenol A (BPA), ethyl-paraben (ETPA), methyl-paraben (MEPA), n‑butyl‑paraben (BUPA), oxybenzone (OXBE), propyl-paraben (PRPA), triclosan (TRCS)), 6 non-specific organophosphate pesticide metabolites (diethyl dithiophosphate (DEDTP), diethyl phosphate (DEP), diethyl thiophosphate (DETP), dimethyl dithiophosphate (DMDTP), dimethyl phosphate (DMP), dimethyl thiophosphate (DMTP)), and 10 phthalate metabolites (mono benzyl phthalate (MBzP), monoethyl phthalate (MEP), mono‑2‑ethyl 5‑carboxypentyl phthalate (MECPP), mono‑2‑ethylhexyl phthalate (MEHP), mono‑2‑ethyl‑5‑hydroxyhexyl phthalate (MEHHP), mono‑2‑ethyl‑5‑oxohexyl phthalate (MEOHP), mono‑4‑methyl‑7‑hydroxyoctyl phthalate (oh-MiNP), mono‑4‑methyl‑7‑oxooctyl phthalate (oxo-MiNP), mono‑iso‑butyl phthalate (MiBP), mono‑n‑butyl phthalate (MnBP)) originating from 6 distinct phthalate parent compounds. The laboratory protocols for the analysis are described elsewhere ([30](#ref-HaugSakhiCequier:2018)).

### Glucocorticosteroids

Urine samples of the night before the day of the visit were used to measure levels of the glucocorticosteroids. These included glucocorticosteroids, glucocorticosteroid metabolites, glucocorticosteroid precursors, glucocorticosteroid precursor metabolites, androgens, and androgen metabolites. A list of the glucocorticosteroids determined in urine samples and used for the present study is given in [Table S7](#supptbl-info-mets).

To assess the levels of glucocorticosteroids and their metabolites, LC-MS/MS analysis was applied at the Applied Metabolomics Research Group, IMIM (Hospital del Mar Medical Research Institute). The laboratory protocols for the analysis are described elsewhere ([31](#ref-MarcosRenauCasals:2014),[32](#ref-Gomez-GomezPozo:2020)).

Three additional markers, total cortisol production, total cortisone production, and total corticosterone production, were computed based on the following: cortisol production as the sum of cortisol and its metabolites (20α-dihydrocortisol (20aDHF), 20β-dihydrocortisol (20bDHF), 5α,20α-cortol (5a20acortol), 5α,20β-cortol (5a20bcortol), 5α-tetrahydrocortisol (5aTHF), 5β,20α-cortol (5b20acortol), 5β,20β-cortol (5b20bcortol), 5β-dihydrocortisol (5bDHF), 5β-tetrahydrocortisol (5bTHF), 6β-hydroxycortisol (6OHF)), cortisone production as the sum of cortisone and its metabolites (20α-dihydrocortisone (20aDHE), 20β-dihydrocortisone (20bDHE), 5α-tetrahydrocortisone (5aTHE), 5β,20α-cortolone (5b20acortolone), 5β,20β-cortolone (5b20bcortolone), 5β-tetrahydrocortisone (5bTHE), 6β-hydroxycortisone (6OHE)), and corticosterone production as the sum of 11-dehydrocorticosterone (A), 17-deoxycortolone (17-DO-cortolone), 5α-tetrahydrocorticosterone (5aTHB), 5β-tetrahydrocorticosterone (5bTHB).

### Neurodevelopment

Neurodevelopmental outcomes were assessed with standardized, non-linguistic, and culturally blind computer tests, including the Attention Network Test (ANT) ([33](#ref-RuedaFanMcCandliss:2004)), which provides a measure of efficiency in three different functions of attention: alerting, orienting, and executive attention. The tests were administered in a standardized way, and with minimal interference from the field workers. Further information can be found in ([29](#ref-MaitreBontCasas:2018)). The outcome of interest for the present study is the hit reaction time standard error (HRT-SE) ([34](#ref-SunyerEsnaolaAlvarez-Pedrerol:2015)), a measure of response speed consistency throughout the test. A high HRT-SE indicates highly variable reactions, and is considered a measure of inattentiveness.

### Confounders

For each research question, defined by a specific type of exposure and outcome, the minimal set of covariates for inclusion in the analyses was selected on the basis of a directed acyclic graph (DAG) built with DAGitty ([35](#ref-TextorvanderZanderGilthorpe:2016)) and ggdag ([36](#ref-Barrett:2023)). The sets of covariates were selected to estimate the total effect of the exposure on the outcome. Further, each minimal adjustment set was *augmented* with precision covariates, defined as the set of parents variable of the outcome that are not parents of the exposure. The adjustment sets are provided in the Supplementary Material as text files compatible with DAGitty. Codebooks for the used covariates, by research question, are provided in Supplementary Tables [2](#supptbl-codebook-1), [3](#supptbl-codebook-2), [4](#supptbl-codebook-3).

* For RQ1 I used creatinine values from HELIX. For RQ3 the ones from the steroids dataset. For RQ2, I included in the model both variables.

## Statistical methods

### Data pre-processing

Concentrations of the glucocorticosteroids were classified as quantifiable, below the limit of quantification (LOQ), possible interference or out of range, and not detected. For each metabolite, we computed the fraction of values below the LOQ and not detected, both within each cohort and overall. We proceeded to impute these values using half the value of the corresponding lower limit of quantification (LLOQ), for those metabolites that had less than 30% of missings within each cohort and 20% of missings overall. Information about the LLOQ for the glucocorticosteroids is provided in [Table S8](#supptbl-lloq-mets). The remaining missing values were imputed using kNN from the VIM R package ([37](#ref-KowarikTempl:2016)), for those metabolites that had less than 40% of remaining missings within each cohort and 30% of remaining missings overall. We used 5 nearest neighbors. We natural log-transformed them to improve model fit, assessed with posterior predictive checks. To do so, replicated data were simulated with the fitted models and compared to the observed data. We used the check\_predictions function from the performance R package using the default arguments ([38](#ref-LudeckeBen-ShacharPatil:2021)). Values of cortisol production and cortisone production were expressed in nanograms per millilitre (ng/ml), whereas values of cortisol metabolism and 11bHSD activity were unitless.

Concentrations of the non-persistent EDCs were classified as quantifiable, below the limit of detection (LOD), possible interference or out of range, and not analysed. Concentrations below the LOD were singly imputed using a quantile regression approach for the imputation of left-censored missing data, as implemented in the impute.QRILC function from the imputeLCMD R package ([39](#ref-lazar2015imputelcmd)). Information about the lower limits of detection can be found in ([30](#ref-HaugSakhiCequier:2018)). Chemicals with more than 70% of observations below the LOD were not considered in the present study. Remaining missing values were imputed similarly using kNN. Values of the chemicals were expressed in grams per litre (g/L).

Missing values in the clinical outcome were imputed similarly using kNN. We natural log-transformed these to improve model fit, assessed with posterior predictive checks. Values of the clinical outcome were expressed in milliseconds (ms).

Missing values in the covariates were imputed similarly using kNN. Categorical covariates were imputed using the maxCat function, which chooses the level with the most occurrences. Creatinine values were expressed in grams per litre.

### Estimation of balancing weights

To reduce the effect of measured confounders on the exposure-outcome association, stabilized balancing weights were estimated using the energy method available in the WeightIt R package ([40](#ref-Greifer:2023)). This methods estimates weights by minimizing an energy statistic related to covariate balance ([41](#ref-HulingGreiferChen:2023)), thus avoiding the need to specify a parametric model. Weights below the 0.1 and above the 0.9 quantiles were trimmed. Trimming might lead to decreased covariate balance and potentially change the estimand, but can also decrease the variability of the weights. Covariate balance was assessed using functionalities provided by the cobalt R package ([42](#ref-Greifer:2023a)). Specifically, we used *Love* plots to visualize covariate balance before and after adjusting.

### G-computation

We estimated MCs with the parametric g-formula, a method of standardization. The parametric g-formula involves the following steps: 1) fit a outcome model including both covariates and balancing weights; 2) create two new datasets identical to the original one but with the exposure shifted according to a user-specified intervention set by a deterministic function of the observed exposure levels; 3) use the outcome model to compute adjusted predictions in the two counterfactual datasets; 4) compute the difference between the means of the adjusted predictions in the counterfactual datasets. The causal parameter of interest was thus specified as the difference in the expected counterfactual outcomes under the shifted exposure levels . In order for this parameter to be identified, the usual causal identifiability conditions (no unmeasured confounding, positivity, and consistency) are required. Since these conditions are likely not satisfied, we focused on the estimation of a statistical estimand that is as close as possible to the causal parameter of interest.

We fit the outcome model using the glm function and a Gaussian family with identity link from base R. The exposure variable was modeled using natural cubic splines with 3 degrees of freedom, to more flexibly capture the average dose-response function (ADRF). When the outcome was a ratio, as was the case for cortisol metabolism and 11bHSD activity, we included the logarithm of its denominator, cortisol and cortisol production, respectively, as a control variable ([43](#ref-BartlettPartnoy:2020)).

To estimate the MCs, we used the avg\_comparisons function from the marginaleffects R package ([44](#ref-Arel-Bundock:2023)). The two counterfactual datasets were obtained by setting the exposures levels to 90th percentile () and the 10th percentile (), for each cohort separately. The MCs were computed using the estimated balancing weights above. Robust standard errors were computed with the sandwich R package, using cohort as variable indicating clustering of observations ([45](#ref-Zeileis:2004),[46](#ref-ZeileisKollGraham:2020)). For each outcome, we report the results as differences between MCs.

We further estimated the ADRF using the avg\_predictions function from the marginaleffects R package, examining 50 exposure values from the 10th to the 90th percentiles of the exposure. As done for the MCs, we included the estimated balancing weights and used cohort as a clustering variable when computing robust standard errors.

### Effect-modification analysis

We tested for possible effect-modification by sex. To do so, balancing weights were estimated separately for each level of the sex variable, and an interaction term between the exposure and sex was included in the outcome model. Similarly, the MCs were aggregated separately for each level of sex. We further tested for significance of the difference between the MCs of males and females.

# Results

[Table 1](#tbl-pop-desc) and [Table S1](#supptbl-pop-desc) provide descriptive statistics for the outcome and covariates for the HELIX subcohort and for each cohort, respectively. Of the 1,301 children of the HELIX subcohort, 1,297 had measurements of the non-persistent EDCs. Measurements of the glucocorticosteroids were available for 1,004 children, of which 980 were matched to the HELIX subcohort. Measurements of both non-persistent EDCs and glucocorticosteroids were available for 976 children of the subcohort. A flowchart describing the sample size for each research question is presented in [Figure S1](#suppfig-flow-pop). The sample consisted of 55% girls. The median HRT-SE was 300 ms (interquartile range (IQR), 231-368), with lower median values for EDEN, MOBA, and INMA, corresponding to the cohorts with older children. At the time of visit, the median age of the children was 8.06 years. The children were mostly Caucasian (90%), and the largest minority were of Pakistani origin (6.2%).

Levels of unprocessed non-persistent EDCs, after imputation of values below the LOD, and glucocorticosteroids, are presented in [Table 2](#tbl-edc-desc), [Table 3](#tbl-met-new-desc), and [Table S6](#supptbl-met-desc).

The effective sample sizes before and after balancing weights estimation are presented in Supplementary Tables [9](#supptbl-balance-1), [10](#supptbl-balance-2), [11](#supptbl-balance-3), while basic summary statistics of the estimated balancing weights are presented in Supplementary Tables [12](#supptbl-weights-1), [13](#supptbl-weights-2), [14](#supptbl-weights-3). As expected, the median value of the weights for each exposure was close to .

[Figure 1](#fig-marginal-1) presents the forest plot for the MCs of the non-persistent EDCs on HRT-SE. For most EDCs, a cohort-specific increase in the levels of the exposures from the 10th to the 90th percentiles was associated with a positive MC, indicating an increase in the values of HRT-SE. Most of the confidence interval (CIs) included the null effect, though. Statistically significant effects were observed for the phenol MEPA (MC and CI: 0.04 (0.01, 0.07)), and the phthalate metabolites oxo-MiNP (MC and CI: 0.02 (0, 0.04)), oh-MiNP (MC and CI: 0.04 (0, 0.08)), and MEHP (MC and CI: 0.04 (0.01, 0.06)). The OP pesticide DETP was strongly negatively associated with HRT-SE (MC and CI: -0.03 (-0.05, 0)).

[Figure 2](#fig-marginal-2) presents the forest plot for the MCs of the non-persistent EDCs on cortisone production, cortisol production, and corticosterone production. For most EDCs, a cohort-specific increase in the levels of the exposures from the 10th to the 90th percentiles was associated with a positive MC, indicating an increase in the total production of these metabolites. Exceptions were BUPA, which was associated with negative MCs for all three outcomes, and MiBP, which was associated with a negative MC for total cortisone production only. The majority of the effects for the phenols and phthalate metabolites included the null. The phenol BPA showed the largest MCs across all three outcomes (cortisone production, MC and CI: 0.26 (0.13, 0.4); cortisol production, MC and CI: 0.27 (0.11, 0.44); corticosterone production, MC and CI: 0.29 (0.11, 0.47)).

[Figure 3](#fig-marginal-3) presents the forest plot for the MCs of the glucocorticosteroids on HRT-SE. All MCs included the null, with no clear indication of directionality of the effect.

## Effect modification by sex

Basic summary statistics of the estimated balancing weights for effect modification are presented in Supplementary Tables [15](#supptbl-weights-1sa), [16](#supptbl-weights-2sa), [17](#supptbl-weights-3sa). As expected, the median value of the weights for each exposure was close to .

[Table 4](#tbl-hypothesis-1and2) presents the results of a hypothesis test for the difference between estimates of the MCs for females and males, for each exposure. Significant differences were present for the phenol OXBE (MC and CI: -0.03 (-0.06, 0)) and the phthalate metabolites MEP (MC and CI: 0.09 (0.02, 0.17)) and MbZP (MC and CI: 0.06 (0, 0.12)). The forest plot of the individual MCs is presented in [Figure S4](#suppfig-marginal-1sa).

[Table 4](#tbl-hypothesis-1and2) presents the results of a hypothesis test for the difference between estimates of the MCs for females and males, for each exposure and outcome. Significant differences were present across all three classes of EDCs and for all outcomes. The largest differences were attributable to the OP pesticides DMTP (cortisol production, MC and CI: 0.21 (0.09, 0.33)) and DETP (corticosterone production, (MC and CI: 0.23 (0.03, 0.43)); cortisone production, (MC and CI: 0.21 (0.05, 0.38))). The forest plots of the individual MCs are presented in [Figure S5](#suppfig-marginal-2sa).

[Table 5](#tbl-hypothesis-3) presents the results of a hypothesis test for the difference between estimates of the MCs for females and males, for each exposure. Significant differences were present for cortisone production (MC and CI: -0.13 (-0.24, -0.03)) and corticosterone production (MC and CI: -0.13 (-0.25, -0.01)). Furthermore, for all exposures, the MCs had opposite sign (positive for males and negative for females). The forest plot of the individual MCs is presented in [Figure S6](#suppfig-marginal-3sa).

# Discussion

The impact of exposure to EDCs on human health has attracted considerable research interest. While research in this area has mainly investigated the effects of prenatal exposure on child neurodevelopment ([2](#Xd81cf38a3b251ec377f8aa13b097ea9d0c190e3)), little is still known about childhood exposure. In this study, consisting of 1,297 children from 6 European birth cohorts, we observed that short-term childhood exposure to non-persistent EDCs had negative effects on HRT-SE and total production of cortisol, cortisone, and corticosterone, although the majority of the CIs included the null effect. Increased production of these glucocorticosteroids did not seem to affect HRT-SE. Some of these effects differed for females and males, including significant differences for the effects of increased production of cortisone and corticosterone on HRT-SE. Specifically, an increased production of these glucocorticosteroids was associated with lower values of HRT-SE for females, and higher values for males. Taken together, these results suggest that these non-persistent EDCs might be responsible for perturbations of the HPA axis’ homeostasis, and that higher levels of these glucocorticosteroids might interfere with different functions of attention in a sex-specific manner.

We are not aware of prior studies specifically investigating the effects of exposure to EDCs in relation to HRT-SE. The literature on EDCs and neurodevelopment in children has mostly focused on OP pesticides ([3](#ref-BouchardBellingerWright:2010),[4](#X2a5c5c17453fffe785b7f0bcffd564283892c6c),[6](#Xa0cc0fdd8206e54b0a9b4bdcd9d2102efd24cb7),[8](#ref-YuDuChiou:2016)), phthalate metabolites ([5](#ref-HuangChenSu:2015),[9](#ref-HuangTsaiChen:2017),[10](#ref-KimHongShin:2017),[17](#ref-VilmandBeckBilenberg:2023)), and BPA ([7](#ref-TewarAuingerBraun:2016),[13](#ref-LiZhangKuang:2018),[14](#X71fca68020aad3c79232160399444b9923ab76e)), in relation to Attention-Deficit / Hyperactivity Disorder (ADHD) ([3](#ref-BouchardBellingerWright:2010),[7](#ref-TewarAuingerBraun:2016),[8](#ref-YuDuChiou:2016),[13](#ref-LiZhangKuang:2018)), and intelligence scales ([4](#X2a5c5c17453fffe785b7f0bcffd564283892c6c)–[6](#Xa0cc0fdd8206e54b0a9b4bdcd9d2102efd24cb7),[9](#ref-HuangTsaiChen:2017),[10](#ref-KimHongShin:2017),[17](#ref-VilmandBeckBilenberg:2023)). Few studies have looked into different classes of EDCs ([15](#ref-ShoaffCoullWeuve:2020) in relation with the Conners Attention Deficit Scale and the Behavior Assessment System for Children,[16](#ref-OhKimKannan:2023) in relation with ADHD symptoms). Overall, and consistent with our results, these studies seem to provide further evidence of the adverse effects of several EDCs on neurodevelopment in children. While not all these studies have investigated effect modification by sex, it seems that these adverse effects are stronger in males. A major limitation of these studies is the reliance on spot urine samples, that might not be representative of long-term exposures.

Our results are consistent with prior epidemiological research that associated exposure to certain EDCs with higher levels of cortisol ([18](#ref-KimLeeMoon:2018)–[20](#ref-SearsLiuLanphear:2023)). There are some differences, though. First, these studies only focus on phthalates, either as individual metabolites or as mixture. Second, exposure assessment in ([19](#ref-SunLiJin:2018)) and ([18](#ref-KimLeeMoon:2018)) was performed during gestation or the first 15 months of life, respectively. Finally, the glucocorticosteroids were measured in cord blood ([19](#ref-SunLiJin:2018)) and hair ([20](#ref-SearsLiuLanphear:2023)). Contrary to these studies, we did find effect modification by sex. We are not aware of other epidemiological studies investigating phthalates metabolites, phenols, and OP pesticides, in relation to urinary glucocorticosteroids in childhood.

We are also not aware of prior epidemiological studies specifically investigating the effects of elevated levels of glucocorticosteroids in relation to HRT-SE, although there is evidence that under- or over-production of glucocorticosteroids interfere with the normal development of the brain ([21](#ref-LupienMcEwenGunnar:2009)). While we did find sex-specific evidence of an effect, their clinical relevance is questionable.

Our findings should be interpreted in light of the following limitations and strengths. Limitations include the cross-sectional design of the present study. Importantly, the non-persistent EDCs were measured in a pool of night and morning urine samples before the clinical visit, to represent exposure over the previous day, whereas the glucocorticosteroids were measured in the night urine sample. Although we included a wide range of confounders there is the possibility, as with other observational studies, of residual confounding, which might lead to a bias away from the null. Some of the confounders indicated in the adjustment sets had to be remove due to large fractions of missing values. There is further the possibility of misspecification of the outcome model, although we included a spline of the exposure to relax some of the linearity assumptions. The use of more data-adaptive learners was excluded due to the relatively small sample size. We finally acknowledge the possibility that some of chemicals might not act independently (mixture effect). Further research is thus warranted.

Strengths of the present study include the use of pooled urine samples for chemical assessment, since it is known that these specific EDCs have very short half-lives ([47](#ref-CasasBasaganaSakhi:2018)). We decided to model both the *treatment* mechanisms, for the estimation of balancing weights, and the outcomes, with traditional covariates adjustment, to try to obtain *doubly robust* effect estimates. Finally, we decided not to interpret our results by focusing on the estimated coefficients of the regression models, but by making use of the g-computation procedure and estimate MCs.

In conclusion, in a study of 1,297 children from 6 European birth cohorts, we observed that (i) exposure to non-persistent EDCs in childhood might have short-term effects on HRT-SE in childhood, (ii) exposure to non-persistent EDCs in childhood might disrupt the HPA axis in childhood, and (iii) disruption of the HPA axis in childhood might have short-term, sex-specific effects on HRT-SE. Future studies should investigate how glucocorticosteroids might mediate the adverse effects of exposure to EDCs on childhood neurodevelopment in larger populations.

# References

1. Grandjean P, Landrigan PJ. [Neurobehavioural effects of developmental toxicity](https://doi.org/10.1016/S1474-4422(13)70278-3). *Lancet Neurol*. 2014;13(3):330–338.

2. Ramírez V, Gálvez-Ontiveros Y, González-Domenech PJ, et al. Role of endocrine disrupting chemicals in children’s neurodevelopment. *Environmental Research* [electronic article]. 2022;203:111890. (<https://www.sciencedirect.com/science/article/pii/S0013935121011853>). (Accessed January 31, 2023)

3. Bouchard MF, Bellinger DC, Wright RO, et al. Attention-Deficit/Hyperactivity Disorder and Urinary Metabolites of Organophosphate Pesticides. *Pediatrics* [electronic article]. 2010;125(6):e1270–e1277. (<https://doi.org/10.1542/peds.2009-3058>). (Accessed December 29, 2023)

4. González-Alzaga B, Hernández AF, Rodríguez-Barranco M, et al. Pre- and postnatal exposures to pesticides and neurodevelopmental effects in children living in agricultural communities from South-Eastern Spain. *Environment International* [electronic article]. 2015;85:229–237. (<https://www.sciencedirect.com/science/article/pii/S0160412015300593>). (Accessed December 29, 2023)

5. Huang H-B, Chen H-Y, Su P-H, et al. Fetal and Childhood Exposure to Phthalate Diesters and Cognitive Function in Children Up to 12 Years of Age: Taiwanese Maternal and Infant Cohort Study. *PLOS ONE* [electronic article]. 2015;10(6):e0131910. (<https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0131910>). (Accessed December 29, 2023)

6. Cartier C, Warembourg C, Le Maner-Idrissi G, et al. Organophosphate Insecticide Metabolites in Prenatal and Childhood Urine Samples and Intelligence Scores at 6 Years of Age: Results from the Mother–Child PELAGIE Cohort (France). *Environmental Health Perspectives* [electronic article]. 2016;124(5):674–680. (<https://ehp.niehs.nih.gov/doi/10.1289/ehp.1409472>). (Accessed December 29, 2023)

7. Tewar S, Auinger P, Braun JM, et al. Association of Bisphenol A exposure and Attention-Deficit/Hyperactivity Disorder in a national sample of U.S. children. *Environmental Research* [electronic article]. 2016;150:112–118. (<https://www.sciencedirect.com/science/article/pii/S0013935116302110>). (Accessed December 29, 2023)

8. Yu C-J, Du J-C, Chiou H-C, et al. Increased risk of attention-deficit/hyperactivity disorder associated with exposure to organophosphate pesticide in Taiwanese children. *Andrology* [electronic article]. 2016;4(4):695–705. (<https://onlinelibrary.wiley.com/doi/abs/10.1111/andr.12183>). (Accessed December 29, 2023)

9. Huang P-C, Tsai C-H, Chen C-C, et al. Intellectual evaluation of children exposed to phthalate-tainted products after the 2011 Taiwan phthalate episode. *Environmental Research* [electronic article]. 2017;156:158–166. (<https://www.sciencedirect.com/science/article/pii/S0013935116309112>). (Accessed December 29, 2023)

10. Kim JI, Hong Y-C, Shin CH, et al. The effects of maternal and children phthalate exposure on the neurocognitive function of 6-year-old children. *Environmental Research* [electronic article]. 2017;156:519–525. (<https://www.sciencedirect.com/science/article/pii/S0013935116312828>). (Accessed December 29, 2023)

11. Furlong MA, Herring A, Buckley JP, et al. Prenatal exposure to organophosphorus pesticides and childhood neurodevelopmental phenotypes. *Environmental Research* [electronic article]. 2017;158:737–747. (<https://www.sciencedirect.com/science/article/pii/S0013935117301044>). (Accessed January 31, 2023)

12. Braun JM. Early-life exposure to EDCs: Role in childhood obesity and neurodevelopment. *Nat Rev Endocrinol* [electronic article]. 2017;13(3, 3):161–173. (<https://www.nature.com/articles/nrendo.2016.186>). (Accessed December 19, 2023)

13. Li Y, Zhang H, Kuang H, et al. Relationship between bisphenol A exposure and attention-deficit/ hyperactivity disorder: A case-control study for primary school children in Guangzhou, China. *Environmental Pollution* [electronic article]. 2018;235:141–149. (<https://www.sciencedirect.com/science/article/pii/S0269749117327884>). (Accessed December 29, 2023)

14. Rodríguez-Carrillo A, Mustieles V, Pérez-Lobato R, et al. Bisphenol A and cognitive function in school-age boys: Is BPA predominantly related to behavior? *NeuroToxicology* [electronic article]. 2019;74:162–171. (<https://www.sciencedirect.com/science/article/pii/S0161813X19300543>). (Accessed December 29, 2023)

15. Shoaff JR, Coull B, Weuve J, et al. Association of Exposure to Endocrine-Disrupting Chemicals During Adolescence With Attention-Deficit/Hyperactivity Disorder–Related Behaviors. *JAMA Network Open* [electronic article]. 2020;3(8):e2015041. (<https://doi.org/10.1001/jamanetworkopen.2020.15041>). (Accessed December 29, 2023)

16. Oh J, Kim K, Kannan K, et al. [Early childhood exposure to environmental phenols and parabens, phthalates, organophosphate pesticides, and trace elements in association with attention deficit hyperactivity disorder (ADHD) symptoms in the CHARGE study](https://doi.org/10.21203/rs.3.rs-2565914/v1). *Res Sq*. 2023;rs.3.rs–2565914.

17. Vilmand M, Beck IH, Bilenberg N, et al. Prenatal and current phthalate exposure and cognitive development in 7-year-old children from the Odense child cohort. *Neurotoxicology and Teratology* [electronic article]. 2023;96:107161. (<https://www.sciencedirect.com/science/article/pii/S0892036223000119>). (Accessed November 16, 2023)

18. Kim JH, Lee J, Moon H-B, et al. Association of phthalate exposures with urinary free cortisol and 8-hydroxy-2’-deoxyguanosine in early childhood. *Science of The Total Environment* [electronic article]. 2018;627:506–513. (<https://www.sciencedirect.com/science/article/pii/S0048969718301475>). (Accessed December 26, 2023)

19. Sun X, Li J, Jin S, et al. Associations between repeated measures of maternal urinary phthalate metabolites during pregnancy and cord blood glucocorticoids. *Environment International* [electronic article]. 2018;121:471–479. (<https://www.sciencedirect.com/science/article/pii/S0160412018315113>). (Accessed November 9, 2023)

20. Sears CG, Liu Y, Lanphear BP, et al. Evaluating mixtures of urinary phthalate metabolites and serum per-/polyfluoroalkyl substances in relation to adolescent hair cortisol: The HOME Study. *American Journal of Epidemiology* [electronic article]. 2023;kwad198. (<https://doi.org/10.1093/aje/kwad198>). (Accessed November 16, 2023)

21. Lupien SJ, McEwen BS, Gunnar MR, et al. Effects of stress throughout the lifespan on the brain, behaviour and cognition. *Nat Rev Neurosci* [electronic article]. 2009;10(6, 6):434–445. (<https://www.nature.com/articles/nrn2639>). (Accessed December 31, 2023)

22. Vrijheid M, Slama R, Robinson O, et al. [The human early-life exposome (HELIX): Project rationale and design](https://doi.org/10.1289/ehp.1307204). *Environ Health Perspect*. 2014;122(6):535–544.

23. Wright J, Small N, Raynor P, et al. Cohort Profile: The Born in Bradford multi-ethnic family cohort study. *International Journal of Epidemiology* [electronic article]. 2013;42(4):978–991. (<https://doi.org/10.1093/ije/dys112>). (Accessed December 19, 2023)

24. Heude B, Forhan A, Slama R, et al. Cohort Profile: The EDEN mother-child cohort on the prenatal and early postnatal determinants of child health and development. *International Journal of Epidemiology* [electronic article]. 2016;45(2):353–363. (<https://doi.org/10.1093/ije/dyv151>). (Accessed November 13, 2023)

25. Guxens M, Ballester F, Espada M, et al. Cohort Profile: The INMA—INfancia y Medio Ambiente—(Environment and Childhood) Project. *International Journal of Epidemiology* [electronic article]. 2012;41(4):930–940. (<https://doi.org/10.1093/ije/dyr054>). (Accessed November 13, 2023)

26. Grazuleviciene R, Danileviciute A, Nadisauskiene R, et al. Maternal Smoking,GSTM1 and GSTT1 Polymorphism and Susceptibility to Adverse Pregnancy Outcomes. *International Journal of Environmental Research and Public Health* [electronic article]. 2009;6(3, 3):1282–1297. (<https://www.mdpi.com/1660-4601/6/3/1282>). (Accessed November 13, 2023)

27. Magnus P, Irgens LM, Haug K, et al. Cohort profile: The Norwegian Mother and Child Cohort Study (MoBa). *International Journal of Epidemiology* [electronic article]. 2006;35(5):1146–1150. (<https://doi.org/10.1093/ije/dyl170>). (Accessed November 13, 2023)

28. Chatzi L, Plana E, Daraki V, et al. Metabolic Syndrome in Early Pregnancy and Risk of Preterm Birth. *American Journal of Epidemiology* [electronic article]. 2009;170(7):829–836. (<https://doi.org/10.1093/aje/kwp211>). (Accessed November 13, 2023)

29. Maitre L, Bont J de, Casas M, et al. Human Early Life Exposome (HELIX) study: A European population-based exposome cohort. *BMJ Open* [electronic article]. 2018;8(9):e021311. (<https://bmjopen.bmj.com/content/8/9/e021311>). (Accessed November 13, 2023)

30. Haug LS, Sakhi AK, Cequier E, et al. In-utero and childhood chemical exposome in six European mother-child cohorts. *Environment International* [electronic article]. 2018;121:751–763. (<https://www.sciencedirect.com/science/article/pii/S016041201831225X>). (Accessed January 17, 2022)

31. Marcos J, Renau N, Casals G, et al. Investigation of endogenous corticosteroids profiles in human urine based on liquid chromatography tandem mass spectrometry. *Analytica Chimica Acta* [electronic article]. 2014;812:92–104. (<https://www.sciencedirect.com/science/article/pii/S0003267013015791>). (Accessed November 13, 2023)

32. Gomez-Gomez A, Pozo OJ. Determination of steroid profile in hair by liquid chromatography tandem mass spectrometry. *Journal of Chromatography A* [electronic article]. 2020;1624:461179. (<https://www.sciencedirect.com/science/article/pii/S0021967320304313>). (Accessed November 13, 2023)

33. Rueda MR, Fan J, McCandliss BD, et al. Development of attentional networks in childhood. *Neuropsychologia* [electronic article]. 2004;42(8):1029–1040. (<https://www.sciencedirect.com/science/article/pii/S0028393204000041>). (Accessed April 12, 2023)

34. Sunyer J, Esnaola M, Alvarez-Pedrerol M, et al. Association between Traffic-Related Air Pollution in Schools and Cognitive Development in Primary School Children: A Prospective Cohort Study. *PLOS Medicine* [electronic article]. 2015;12(3):e1001792. (<https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001792>). (Accessed November 21, 2023)

35. Textor J, van der Zander B, Gilthorpe MS, et al. Robust causal inference using directed acyclic graphs: The R package “dagitty.” *International Journal of Epidemiology* [electronic article]. 2016;45(6):1887–1894. (<https://doi.org/10.1093/ije/dyw341>). (Accessed September 22, 2023)

36. Barrett M. Ggdag: Analyze and Create Elegant Directed Acyclic Graphs. 2023;(<https://github.com/r-causal/ggdag>)

37. Kowarik A, Templ M. Imputation with the R Package VIM. *Journal of Statistical Software* [electronic article]. 2016;74:1–16. (<https://doi.org/10.18637/jss.v074.i07>). (Accessed January 17, 2022)

38. Lüdecke D, Ben-Shachar MS, Patil I, et al. [performance: An R package for assessment, comparison and testing of statistical models](https://doi.org/10.21105/joss.03139). *Journal of Open Source Software*. 2021;6(60):3139.

39. Lazar C. imputeLCMD: A collection of methods for left-censored missing data imputation. *R package, version*. 2015;2.

40. Greifer N. WeightIt: Weighting for covariate balance in observational studies. 2023.

41. Huling JD, Greifer N, Chen G. Independence Weights for Causal Inference with Continuous Treatments. *Journal of the American Statistical Association* [electronic article]. 2023;0(0):1–14. (<https://doi.org/10.1080/01621459.2023.2213485>). (Accessed September 15, 2023)

42. Greifer N. Cobalt: Covariate balance tables and plots. 2023.

43. Bartlett RP, Partnoy F. The Ratio Problem. *SSRN Journal* [electronic article]. 2020;(<https://www.ssrn.com/abstract=3605606>). (Accessed November 14, 2023)

44. Arel-Bundock V. Marginaleffects: Predictions, comparisons, slopes, marginal means, and hypothesis tests. 2023.(<https://marginaleffects.com/>)

45. Zeileis A. [Econometric computing with HC and HAC covariance matrix estimators](https://doi.org/10.18637/jss.v011.i10). *Journal of Statistical Software*. 2004;11(10):1–17.

46. Zeileis A, Köll S, Graham N. [Various versatile variances: An object-oriented implementation of clustered covariances in R](https://doi.org/10.18637/jss.v095.i01). *Journal of Statistical Software*. 2020;95(1):1–36.

47. Casas M, Basagaña X, Sakhi AK, et al. Variability of urinary concentrations of non-persistent chemicals in pregnant women and school-aged children. *Environ. Int.* [electronic article]. 2018;121(Pt 1, Pt 1):561–573. (<http://dx.doi.org/10.1016/j.envint.2018.09.046>)

# Tables for descriptive data

## Study populations

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Table 1: **Participant characteristics (HELIX subcohort; 2013-2016).**   | **Characteristic** | **N = 1,297***a* | | --- | --- | | Hit reaction time standard error (ms) | 299.6 (231.3, 368.2) | | Unknown | 18 | | Age (years) | 8.1 (6.5, 8.9) | | Child breastfeeding | 1,093.0 (84.7%) | | Unknown | 6 | | Height (m) | 1.3 (1.2, 1.4) | | Weight (kg) | 26.9 (22.9, 32.6) | | Head circumference (cm) | 51.8 (50.6, 52.9) | | Unknown | 3 | | Fast food/take away (times/week) | 0.1 (0.1, 0.5) | | Unknown | 7 | | Organic food (times/week) | 0.5 (0.0, 3.0) | | Unknown | 7 | | Fish and seafood (times/week) | 2.0 (1.1, 3.5) | | Unknown | 5 | | Fruits (times/week) | 9.0 (5.9, 18.0) | | Unknown | 7 | | Vegetables (times/week) | 6.5 (4.0, 10.0) | | Unknown | 6 | | Tobacco consumption |  | | Non-smoker and has never smoked | 681.0 (52.6%) | | Non-smoker but previously smoked although not daily | 163.0 (12.6%) | | Non-smoker but previously smoked daily | 186.0 (14.4%) | | Smoker but not daily | 64.0 (4.9%) | | Daily smoker | 200.0 (15.5%) | | Unknown | 3 | | cohort |  | | BIB | 204.0 (15.7%) | | EDEN | 198.0 (15.3%) | | KANC | 203.0 (15.7%) | | MOBA | 272.0 (21.0%) | | RHEA | 199.0 (15.3%) | | SAB | 221.0 (17.0%) | | Creatinine pooled sample (g/l) | 1.0 (0.8, 1.2) | | Mood before assessment |  | | Usual | 1,232.0 (95.1%) | | Not usual | 64.0 (4.9%) | | Unknown | 1 | | Rest before assessment |  | | Yes | 1,209.0 (93.3%) | | Not as well as usual | 87.0 (6.7%) | | Unknown | 1 | | Child ethnicity |  | | African | 7.0 (0.5%) | | Asian | 21.0 (1.6%) | | Caucasian | 1,157.0 (90.0%) | | Native American | 2.0 (0.2%) | | Other | 19.0 (1.5%) | | Pakistani | 80.0 (6.2%) | | White non European | 0.0 (0.0%) | | Unknown | 11 | | Family affluence scale |  | | 0 | 6.0 (0.5%) | | 1 | 12.0 (0.9%) | | 2 | 28.0 (2.2%) | | 3 | 92.0 (7.1%) | | 4 | 174.0 (13.4%) | | 5 | 325.0 (25.1%) | | 6 | 410.0 (31.7%) | | 7 | 248.0 (19.2%) | | Unknown | 2 | | Financial situation |  | | Living comfortably | 412.0 (31.9%) | | Doing alright | 414.0 (32.1%) | | Getting by | 331.0 (25.6%) | | Finding it quite difficult | 86.0 (6.7%) | | Finding it very difficult | 40.0 (3.1%) | | Does not wish to answer | 8.0 (0.6%) | | Unknown | 6 | | Marital status |  | | Living with the father | 39.0 (3.0%) | | Living alone | 1,212.0 (94.5%) | | Other situation | 31.0 (2.4%) | | Unknown | 15 | | Pregnancy maternal active smoking | 190.0 (15.1%) | | Unknown | 40 | | Pregnancy maternal passive smoking | 514.0 (40.3%) | | Unknown | 21 | | Child neuropsychological diagnosis | 95.0 (7.3%) | | Date of test (season) |  | | autumn | 300.0 (23.2%) | | spring | 358.0 (27.7%) | | summer | 297.0 (23.0%) | | winter | 339.0 (26.2%) | | Unknown | 3 | | Sex |  | | Male | 587.0 (45.3%) | | Female | 710.0 (54.7%) | | Fasting time | 3.3 (2.8, 4.0) | | Creatinine night sample (g/l) | 1.7 (0.9, 3.0) | | Unknown | 321 | | *a*Median (IQR); n (%) | | |

## Endocrine disruptors

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Table 2: **Participants endocrine disruptors concentrations expressed in grams/L (HELIX subcohort; 2013-2016).**   | **Characteristic** | **N = 1,297***a* | | --- | --- | | **OP pesticide metabolites** | | | DMP | 0.4 (0.3, 4.6); 6.0 (0.5) | | DMTP | 2.8 (1.2, 6.3); 1.0 (0.1) | | DEP | 1.8 (0.4, 4.6); 2.0 (0.2) | | DETP | 0.1 (0.1, 1.7); 21.0 (1.6) | | **Phenols** | | | MEPA | 6.3 (3.1, 24.1); 2.0 (0.2) | | ETPA | 0.7 (0.4, 1.2); 3.0 (0.2) | | PRPA | 0.2 (0.0, 1.6); 17.0 (1.3) | | BPA | 3.8 (2.3, 7.0); 12.0 (0.9) | | BUPA | 0.1 (0.0, 0.1); 5.0 (0.4) | | OXBE | 2.0 (0.8, 6.6); 0.0 (0.0) | | TRCS | 0.6 (0.3, 1.5); 0.0 (0.0) | | **Phthalate metabolites** | | | MEP | 32.5 (15.0, 79.2); 0.0 (0.0) | | MiBP | 40.2 (24.5, 71.1); 0.0 (0.0) | | MnBP | 22.7 (14.5, 38.8); 0.0 (0.0) | | MBzP | 4.8 (2.7, 8.7); 1.0 (0.1) | | MEHP | 2.8 (1.6, 5.1); 41.0 (3.2) | | MEHHP | 19.3 (11.4, 33.1); 3.0 (0.2) | | MEOHP | 12.2 (7.1, 20.4); 1.0 (0.1) | | MECPP | 32.8 (19.9, 57.6); 1.0 (0.1) | | oh-MiNP | 5.0 (3.1, 9.3); 0.0 (0.0) | | oxo-MiNP | 2.7 (1.7, 5.0); 0.0 (0.0) | | *a*Median (IQR); N missing (% missing) | | |

## Glucocorticosteroids

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Table 3: **Participants derived glucocorticosteroids concentrations expressed in ng/ml, by cohort and overall (HELIX subcohort; 2013-2016).**   | **Characteristic** | **N = 1,004***a* | **N = 976***a,b* | | --- | --- | --- | | cortisol production | 4,607.9 (2,860.5, 6,787.6); 18.0 (1.8) | 4,559.5 (2,834.5, 6,731.7); 17.0 (1.7) | | cortisone production | 4,608.1 (2,920.8, 6,843.9); 19.0 (1.9) | 4,580.7 (2,899.3, 6,800.5); 18.0 (1.8) | | corticosterone production | 257.8 (157.9, 410.5); 3.0 (0.3) | 256.7 (157.5, 409.7); 3.0 (0.3) | | *a*Median (IQR); N missing (% missing) | | | | *b*Measurements available for the HELIX subcohort. | | | |

# Tables for other analyses

## Marginal hypotheses for effect modification

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Table 4: **Pairwise differences between sex-specific marginal contrasts for the effect of a decrease from the 90th to the 10th percentile of EDCs on HRT-SE, expressed in ms, and the glucocorticosteroids, expressed in ng/ml (HELIX subcohort; 2013-2016).**   |  | hitrtse*a* | corticosterone production*a* | cortisol production*a* | cortisone production*a* | | --- | --- | --- | --- | --- | | **OP pesticide metabolites** | | | | | | DMTP | 0 (-0.1, 0.1) | 0.04 (-0.09, 0.18) | 0.21 (0.09, 0.33)\* | 0.15 (-0.04, 0.34) | | DMP | 0.03 (-0.03, 0.08) | 0 (-0.19, 0.18) | 0.03 (-0.06, 0.13) | 0.06 (-0.1, 0.23) | | DETP | -0.02 (-0.12, 0.07) | 0.23 (0.03, 0.43)\* | 0.18 (-0.02, 0.38) | 0.21 (0.05, 0.38)\* | | DEP | -0.01 (-0.03, 0.02) | 0.01 (-0.18, 0.2) | 0.1 (-0.12, 0.33) | 0.05 (-0.16, 0.25) | | **Phenols** | | | | | | TRCS | 0 (-0.03, 0.03) | 0.04 (-0.11, 0.19) | 0.05 (-0.09, 0.19) | 0.09 (0.04, 0.14)\* | | PRPA | -0.02 (-0.08, 0.04) | 0.11 (-0.02, 0.23) | 0.09 (-0.1, 0.27) | 0.11 (-0.01, 0.23) | | OXBE | -0.03 (-0.06, 0) | 0.21 (-0.06, 0.48) | 0.08 (-0.15, 0.31) | 0.07 (-0.13, 0.27) | | MEPA | -0.03 (-0.09, 0.03) | 0.11 (0, 0.21) | 0.14 (0.01, 0.27)\* | 0.1 (0.02, 0.19)\* | | ETPA | -0.02 (-0.06, 0.03) | 0.13 (-0.01, 0.28) | 0.09 (-0.11, 0.29) | 0.12 (-0.1, 0.34) | | BUPA | 0.02 (-0.02, 0.07) | 0.11 (-0.02, 0.24) | 0.13 (0.04, 0.21)\* | 0.01 (-0.09, 0.11) | | BPA | -0.04 (-0.09, 0.02) | 0.14 (0.03, 0.26)\* | 0.11 (-0.02, 0.24) | 0.07 (-0.06, 0.21) | | **Phthalate metabolites** | | | | | | oxo-MiNP | 0.02 (-0.02, 0.05) | 0.07 (-0.1, 0.23) | 0.11 (-0.07, 0.28) | 0.09 (-0.02, 0.2) | | oh-MiNP | -0.05 (-0.11, 0.01) | 0.1 (-0.07, 0.27) | 0.15 (0, 0.29) | 0.14 (0, 0.27) | | MnBP | 0.03 (-0.09, 0.14) | 0.09 (-0.19, 0.37) | 0.05 (-0.19, 0.29) | 0.11 (-0.05, 0.27) | | MiBP | 0.03 (-0.09, 0.14) | -0.03 (-0.25, 0.19) | 0.05 (-0.19, 0.28) | 0.02 (-0.13, 0.17) | | MEP | 0.09 (0.02, 0.17)\* | -0.12 (-0.29, 0.04) | -0.12 (-0.2, -0.04)\* | -0.03 (-0.18, 0.13) | | MEOHP | -0.01 (-0.09, 0.08) | 0.1 (-0.09, 0.29) | 0.1 (0.01, 0.19)\* | 0.01 (-0.07, 0.09) | | MEHP | -0.01 (-0.11, 0.09) | 0.14 (0.04, 0.24)\* | 0.18 (0.08, 0.27)\* | 0.14 (0.03, 0.26)\* | | MEHHP | -0.02 (-0.11, 0.08) | 0.08 (-0.13, 0.28) | 0.11 (-0.01, 0.22) | 0.02 (-0.06, 0.1) | | MECPP | 0 (-0.09, 0.08) | 0.06 (-0.12, 0.24) | 0.07 (0.01, 0.14)\* | 0.02 (-0.08, 0.11) | | MBzP | 0.06 (0, 0.12) | 0.01 (-0.05, 0.07) | 0 (-0.11, 0.12) | 0.07 (-0.04, 0.18) | | *a*Estimate and 95% CI. | | | | | |

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Table 5: **Pairwise differences between sex-specific marginal contrasts for the effect of a decrease from the 90th to the 10th percentile of the glucocorticosteroids on HRT-SE expressed in ms (HELIX subcohort; 2013-2016).**   |  | hitrtse*a* | | --- | --- | | **Glucocorticosteroids** | | | cortisone prod. | -0.13 (-0.24, -0.03)\* | | cortisol prod. | -0.1 (-0.24, 0.04) | | corticost. prod. | -0.13 (-0.25, -0.01)\* | | *a*Estimate and 95% CI. | | |

# Figures for main results

## Marginal contrasts

|  |
| --- |
| Figure 1: **Marginal contrasts for the effect of a decrease from the 90th to the 10th percentile of the EDCs on HRT-SE expressed in ms (HELIX subcohort; 2013-2016).** Circles indicate effect estimates. Solid lines indicate the CI. |

|  |
| --- |
| Figure 2: **Marginal contrasts for the effect of a decrease from the 90th to the 10th percentile of the EDCs on the glucocorticosteroids expressed in ng/ml (HELIX subcohort; 2013-2016).** Circles, triangles, and squares indicate effect estimates. Solid lines indicate the CI. |

|  |
| --- |
| Figure 3: **Marginal contrasts for the effect of a decrease from the 90th to the 10th percentile of the glucocorticosteroids on HRT-SE expressed in ms (HELIX subcohort; 2013-2016).** Circles indicate effect estimates. Solid lines indicate the CI. |

* Files for supplementary data must be accompanied by a summary of the file names and types.

# Supplementary information

## Directed Acyclic Graphs

dag {  
age\_child  
biomarker  
breastfeeding  
bw  
characteristics\_child  
chemical [exposure]  
child\_diet  
child\_smoking  
cohort  
creatinine  
envFactors\_visit  
ethnicity\_child  
ethnicity\_mother  
familySEP  
gestational\_age  
maternalAlcohol\_preg  
maternalDiet\_preg  
maternalSEP\_preg  
maternalSmoking\_preg  
neuropsychologicalDiagnosis\_child  
outcome [outcome]  
paternalSEP\_preg  
season\_visit  
sex\_child  
time\_lastMeal  
type\_sample  
age\_child -> biomarker  
age\_child -> characteristics\_child  
age\_child -> creatinine  
age\_child -> outcome  
age\_child -> type\_sample  
biomarker -> outcome  
breastfeeding -> neuropsychologicalDiagnosis\_child  
breastfeeding -> outcome  
bw -> characteristics\_child  
bw -> neuropsychologicalDiagnosis\_child  
characteristics\_child -> biomarker  
characteristics\_child -> chemical  
characteristics\_child -> creatinine  
characteristics\_child -> outcome  
chemical -> biomarker  
chemical -> outcome  
child\_diet -> biomarker  
child\_diet -> characteristics\_child  
child\_diet -> chemical  
child\_diet -> outcome  
child\_smoking -> biomarker  
child\_smoking -> characteristics\_child  
child\_smoking -> creatinine  
child\_smoking -> outcome  
cohort -> biomarker  
cohort -> bw  
cohort -> characteristics\_child  
cohort -> chemical  
cohort -> child\_diet  
cohort -> creatinine  
cohort -> outcome  
creatinine -> biomarker  
creatinine -> chemical  
creatinine -> outcome  
envFactors\_visit -> outcome  
ethnicity\_child -> biomarker  
ethnicity\_child -> bw  
ethnicity\_child -> characteristics\_child  
ethnicity\_child -> chemical  
ethnicity\_child -> child\_diet  
ethnicity\_child -> child\_smoking  
ethnicity\_child -> creatinine  
ethnicity\_child -> neuropsychologicalDiagnosis\_child  
ethnicity\_child -> outcome  
ethnicity\_mother -> biomarker  
ethnicity\_mother -> breastfeeding  
ethnicity\_mother -> bw  
ethnicity\_mother -> characteristics\_child  
ethnicity\_mother -> child\_diet  
ethnicity\_mother -> familySEP  
ethnicity\_mother -> maternalAlcohol\_preg  
ethnicity\_mother -> maternalDiet\_preg  
ethnicity\_mother -> maternalSEP\_preg  
ethnicity\_mother -> maternalSmoking\_preg  
ethnicity\_mother -> neuropsychologicalDiagnosis\_child  
ethnicity\_mother -> outcome  
familySEP -> biomarker  
familySEP -> characteristics\_child  
familySEP -> chemical  
familySEP -> child\_diet  
familySEP -> child\_smoking  
familySEP -> creatinine  
familySEP -> outcome  
gestational\_age -> bw  
gestational\_age -> characteristics\_child  
gestational\_age -> neuropsychologicalDiagnosis\_child  
maternalAlcohol\_preg -> bw  
maternalAlcohol\_preg -> characteristics\_child  
maternalAlcohol\_preg -> neuropsychologicalDiagnosis\_child  
maternalAlcohol\_preg -> outcome  
maternalDiet\_preg -> characteristics\_child  
maternalDiet\_preg -> neuropsychologicalDiagnosis\_child  
maternalDiet\_preg -> outcome  
maternalSEP\_preg -> breastfeeding  
maternalSEP\_preg -> bw  
maternalSEP\_preg -> characteristics\_child  
maternalSEP\_preg -> familySEP  
maternalSEP\_preg -> maternalAlcohol\_preg  
maternalSEP\_preg -> maternalDiet\_preg  
maternalSEP\_preg -> maternalSmoking\_preg  
maternalSEP\_preg -> neuropsychologicalDiagnosis\_child  
maternalSEP\_preg -> outcome  
maternalSmoking\_preg -> bw  
maternalSmoking\_preg -> characteristics\_child  
maternalSmoking\_preg -> neuropsychologicalDiagnosis\_child  
maternalSmoking\_preg -> outcome  
neuropsychologicalDiagnosis\_child -> outcome  
paternalSEP\_preg -> breastfeeding  
paternalSEP\_preg -> bw  
paternalSEP\_preg -> characteristics\_child  
paternalSEP\_preg -> familySEP  
paternalSEP\_preg -> maternalAlcohol\_preg  
paternalSEP\_preg -> maternalDiet\_preg  
paternalSEP\_preg -> maternalSmoking\_preg  
paternalSEP\_preg -> neuropsychologicalDiagnosis\_child  
paternalSEP\_preg -> outcome  
season\_visit -> biomarker  
season\_visit -> chemical  
sex\_child -> biomarker  
sex\_child -> characteristics\_child  
sex\_child -> chemical  
sex\_child -> child\_diet  
sex\_child -> child\_smoking  
sex\_child -> creatinine  
sex\_child -> neuropsychologicalDiagnosis\_child  
sex\_child -> outcome  
sex\_child -> type\_sample  
time\_lastMeal -> biomarker  
time\_lastMeal -> chemical  
type\_sample -> chemical  
type\_sample -> creatinine  
}

dag {  
age\_child  
biomarker [outcome]  
breastfeeding  
bw  
characteristics\_child  
chemical [exposure]  
child\_diet  
child\_smoking  
cohort  
creatinine  
envFactors\_visit  
ethnicity\_child  
ethnicity\_mother  
familySEP  
gestational\_age  
maternalAlcohol\_preg  
maternalDiet\_preg  
maternalSEP\_preg  
maternalSmoking\_preg  
neuropsychologicalDiagnosis\_child  
outcome  
paternalSEP\_preg  
season\_visit  
sex\_child  
time\_lastMeal  
type\_sample  
age\_child -> biomarker  
age\_child -> characteristics\_child  
age\_child -> creatinine  
age\_child -> outcome  
age\_child -> type\_sample  
biomarker -> outcome  
breastfeeding -> neuropsychologicalDiagnosis\_child  
breastfeeding -> outcome  
bw -> characteristics\_child  
bw -> neuropsychologicalDiagnosis\_child  
characteristics\_child -> biomarker  
characteristics\_child -> chemical  
characteristics\_child -> creatinine  
characteristics\_child -> outcome  
chemical -> biomarker  
chemical -> outcome  
child\_diet -> biomarker  
child\_diet -> characteristics\_child  
child\_diet -> chemical  
child\_diet -> outcome  
child\_smoking -> biomarker  
child\_smoking -> characteristics\_child  
child\_smoking -> creatinine  
child\_smoking -> outcome  
cohort -> biomarker  
cohort -> bw  
cohort -> characteristics\_child  
cohort -> chemical  
cohort -> child\_diet  
cohort -> creatinine  
cohort -> outcome  
creatinine -> biomarker  
creatinine -> chemical  
creatinine -> outcome  
envFactors\_visit -> outcome  
ethnicity\_child -> biomarker  
ethnicity\_child -> bw  
ethnicity\_child -> characteristics\_child  
ethnicity\_child -> chemical  
ethnicity\_child -> child\_diet  
ethnicity\_child -> child\_smoking  
ethnicity\_child -> creatinine  
ethnicity\_child -> neuropsychologicalDiagnosis\_child  
ethnicity\_child -> outcome  
ethnicity\_mother -> biomarker  
ethnicity\_mother -> breastfeeding  
ethnicity\_mother -> bw  
ethnicity\_mother -> characteristics\_child  
ethnicity\_mother -> child\_diet  
ethnicity\_mother -> familySEP  
ethnicity\_mother -> maternalAlcohol\_preg  
ethnicity\_mother -> maternalDiet\_preg  
ethnicity\_mother -> maternalSEP\_preg  
ethnicity\_mother -> maternalSmoking\_preg  
ethnicity\_mother -> neuropsychologicalDiagnosis\_child  
ethnicity\_mother -> outcome  
familySEP -> biomarker  
familySEP -> characteristics\_child  
familySEP -> chemical  
familySEP -> child\_diet  
familySEP -> child\_smoking  
familySEP -> creatinine  
familySEP -> outcome  
gestational\_age -> bw  
gestational\_age -> characteristics\_child  
gestational\_age -> neuropsychologicalDiagnosis\_child  
maternalAlcohol\_preg -> bw  
maternalAlcohol\_preg -> characteristics\_child  
maternalAlcohol\_preg -> neuropsychologicalDiagnosis\_child  
maternalAlcohol\_preg -> outcome  
maternalDiet\_preg -> characteristics\_child  
maternalDiet\_preg -> neuropsychologicalDiagnosis\_child  
maternalDiet\_preg -> outcome  
maternalSEP\_preg -> breastfeeding  
maternalSEP\_preg -> bw  
maternalSEP\_preg -> characteristics\_child  
maternalSEP\_preg -> familySEP  
maternalSEP\_preg -> maternalAlcohol\_preg  
maternalSEP\_preg -> maternalDiet\_preg  
maternalSEP\_preg -> maternalSmoking\_preg  
maternalSEP\_preg -> neuropsychologicalDiagnosis\_child  
maternalSEP\_preg -> outcome  
maternalSmoking\_preg -> bw  
maternalSmoking\_preg -> characteristics\_child  
maternalSmoking\_preg -> neuropsychologicalDiagnosis\_child  
maternalSmoking\_preg -> outcome  
neuropsychologicalDiagnosis\_child -> outcome  
paternalSEP\_preg -> breastfeeding  
paternalSEP\_preg -> bw  
paternalSEP\_preg -> characteristics\_child  
paternalSEP\_preg -> familySEP  
paternalSEP\_preg -> maternalAlcohol\_preg  
paternalSEP\_preg -> maternalDiet\_preg  
paternalSEP\_preg -> maternalSmoking\_preg  
paternalSEP\_preg -> neuropsychologicalDiagnosis\_child  
paternalSEP\_preg -> outcome  
season\_visit -> biomarker  
season\_visit -> chemical  
sex\_child -> biomarker  
sex\_child -> characteristics\_child  
sex\_child -> chemical  
sex\_child -> child\_diet  
sex\_child -> child\_smoking  
sex\_child -> creatinine  
sex\_child -> neuropsychologicalDiagnosis\_child  
sex\_child -> outcome  
sex\_child -> type\_sample  
time\_lastMeal -> biomarker  
time\_lastMeal -> chemical  
type\_sample -> chemical  
type\_sample -> creatinine  
}

dag {  
age\_child  
biomarker [exposure]  
breastfeeding  
bw  
characteristics\_child  
chemical  
child\_diet  
child\_smoking  
cohort  
creatinine  
envFactors\_visit  
ethnicity\_child  
ethnicity\_mother  
familySEP  
gestational\_age  
maternalAlcohol\_preg  
maternalDiet\_preg  
maternalSEP\_preg  
maternalSmoking\_preg  
neuropsychologicalDiagnosis\_child  
outcome [outcome]  
paternalSEP\_preg  
season\_visit  
sex\_child  
time\_lastMeal  
type\_sample  
age\_child -> biomarker  
age\_child -> characteristics\_child  
age\_child -> creatinine  
age\_child -> outcome  
age\_child -> type\_sample  
biomarker -> outcome  
breastfeeding -> neuropsychologicalDiagnosis\_child  
breastfeeding -> outcome  
bw -> characteristics\_child  
bw -> neuropsychologicalDiagnosis\_child  
characteristics\_child -> biomarker  
characteristics\_child -> chemical  
characteristics\_child -> creatinine  
characteristics\_child -> outcome  
chemical -> biomarker  
chemical -> outcome  
child\_diet -> biomarker  
child\_diet -> characteristics\_child  
child\_diet -> chemical  
child\_diet -> outcome  
child\_smoking -> biomarker  
child\_smoking -> characteristics\_child  
child\_smoking -> creatinine  
child\_smoking -> outcome  
cohort -> biomarker  
cohort -> bw  
cohort -> characteristics\_child  
cohort -> chemical  
cohort -> child\_diet  
cohort -> creatinine  
cohort -> outcome  
creatinine -> biomarker  
creatinine -> chemical  
creatinine -> outcome  
envFactors\_visit -> outcome  
ethnicity\_child -> biomarker  
ethnicity\_child -> bw  
ethnicity\_child -> characteristics\_child  
ethnicity\_child -> chemical  
ethnicity\_child -> child\_diet  
ethnicity\_child -> child\_smoking  
ethnicity\_child -> creatinine  
ethnicity\_child -> neuropsychologicalDiagnosis\_child  
ethnicity\_child -> outcome  
ethnicity\_mother -> biomarker  
ethnicity\_mother -> breastfeeding  
ethnicity\_mother -> bw  
ethnicity\_mother -> characteristics\_child  
ethnicity\_mother -> child\_diet  
ethnicity\_mother -> familySEP  
ethnicity\_mother -> maternalAlcohol\_preg  
ethnicity\_mother -> maternalDiet\_preg  
ethnicity\_mother -> maternalSEP\_preg  
ethnicity\_mother -> maternalSmoking\_preg  
ethnicity\_mother -> neuropsychologicalDiagnosis\_child  
ethnicity\_mother -> outcome  
familySEP -> biomarker  
familySEP -> characteristics\_child  
familySEP -> chemical  
familySEP -> child\_diet  
familySEP -> child\_smoking  
familySEP -> creatinine  
familySEP -> outcome  
gestational\_age -> bw  
gestational\_age -> characteristics\_child  
gestational\_age -> neuropsychologicalDiagnosis\_child  
maternalAlcohol\_preg -> bw  
maternalAlcohol\_preg -> characteristics\_child  
maternalAlcohol\_preg -> neuropsychologicalDiagnosis\_child  
maternalAlcohol\_preg -> outcome  
maternalDiet\_preg -> characteristics\_child  
maternalDiet\_preg -> neuropsychologicalDiagnosis\_child  
maternalDiet\_preg -> outcome  
maternalSEP\_preg -> breastfeeding  
maternalSEP\_preg -> bw  
maternalSEP\_preg -> characteristics\_child  
maternalSEP\_preg -> familySEP  
maternalSEP\_preg -> maternalAlcohol\_preg  
maternalSEP\_preg -> maternalDiet\_preg  
maternalSEP\_preg -> maternalSmoking\_preg  
maternalSEP\_preg -> neuropsychologicalDiagnosis\_child  
maternalSEP\_preg -> outcome  
maternalSmoking\_preg -> bw  
maternalSmoking\_preg -> characteristics\_child  
maternalSmoking\_preg -> neuropsychologicalDiagnosis\_child  
maternalSmoking\_preg -> outcome  
neuropsychologicalDiagnosis\_child -> outcome  
paternalSEP\_preg -> breastfeeding  
paternalSEP\_preg -> bw  
paternalSEP\_preg -> characteristics\_child  
paternalSEP\_preg -> familySEP  
paternalSEP\_preg -> maternalAlcohol\_preg  
paternalSEP\_preg -> maternalDiet\_preg  
paternalSEP\_preg -> maternalSmoking\_preg  
paternalSEP\_preg -> neuropsychologicalDiagnosis\_child  
paternalSEP\_preg -> outcome  
season\_visit -> biomarker  
season\_visit -> chemical  
sex\_child -> biomarker  
sex\_child -> characteristics\_child  
sex\_child -> chemical  
sex\_child -> child\_diet  
sex\_child -> child\_smoking  
sex\_child -> creatinine  
sex\_child -> neuropsychologicalDiagnosis\_child  
sex\_child -> outcome  
sex\_child -> type\_sample  
time\_lastMeal -> biomarker  
time\_lastMeal -> chemical  
type\_sample -> chemical  
type\_sample -> creatinine  
}

# Supplementary tables

## Tables for descriptive data

### Study populations

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| | **Characteristic** | **Overall**, N = 1,297*a* | **BIB**, N = 204*a* | **EDEN**, N = 198*a* | **KANC**, N = 203*a* | **MOBA**, N = 272*a* | **RHEA**, N = 199*a* | **SAB**, N = 221*a* | | --- | --- | --- | --- | --- | --- | --- | --- | | Hit reaction time standard error (ms) | 299.6 (231.3, 368.2) | 355.1 (292.1, 397.5) | 237.7 (184.7, 307.0) | 368.4 (324.2, 406.6) | 248.7 (193.0, 300.9) | 340.9 (281.1, 399.2) | 256.0 (197.4, 313.8) | | Unknown | 18 | 3 | 11 | 0 | 0 | 1 | 3 | | Age (years) | 8.1 (6.5, 8.9) | 6.6 (6.5, 6.8) | 10.9 (10.4, 11.2) | 6.4 (6.1, 6.9) | 8.5 (8.2, 8.8) | 6.5 (6.4, 6.6) | 8.8 (8.4, 9.3) | | Child breastfeeding | 1,093.0 (84.7%) | 147.0 (72.4%) | 128.0 (65.0%) | 187.0 (92.6%) | 260.0 (96.3%) | 176.0 (88.4%) | 195.0 (88.6%) | | Unknown | 6 | 1 | 1 | 1 | 2 | 0 | 1 | | Height (m) | 1.3 (1.2, 1.4) | 1.2 (1.2, 1.2) | 1.4 (1.4, 1.5) | 1.2 (1.2, 1.3) | 1.3 (1.3, 1.4) | 1.2 (1.2, 1.2) | 1.3 (1.3, 1.4) | | Weight (kg) | 26.9 (22.9, 32.6) | 22.3 (20.3, 25.0) | 35.7 (32.4, 41.2) | 23.6 (21.4, 27.1) | 28.5 (25.7, 31.6) | 23.3 (21.2, 27.2) | 30.7 (26.8, 36.5) | | Head circumference (cm) | 51.8 (50.6, 52.9) | 51.4 (50.3, 52.3) | 50.5 (49.5, 52.0) | 52.0 (51.0, 53.0) | 52.5 (51.5, 53.6) | 51.2 (50.2, 52.0) | 52.3 (51.3, 53.3) | | Unknown | 3 | 0 | 0 | 0 | 0 | 3 | 0 | | Fast food/take away (times/week) | 0.1 (0.1, 0.5) | 0.5 (0.1, 1.0) | 0.1 (0.1, 0.5) | 0.1 (0.0, 0.1) | 0.1 (0.1, 0.5) | 0.5 (0.1, 0.5) | 0.1 (0.1, 0.5) | | Unknown | 7 | 0 | 0 | 2 | 0 | 0 | 5 | | Organic food (times/week) | 0.5 (0.0, 3.0) | 0.0 (0.0, 0.5) | 0.5 (0.1, 3.0) | 1.0 (0.1, 3.0) | 1.0 (0.5, 3.0) | 0.0 (0.0, 1.0) | 0.0 (0.0, 0.5) | | Unknown | 7 | 0 | 0 | 2 | 0 | 0 | 5 | | Fish and seafood (times/week) | 2.0 (1.1, 3.5) | 2.0 (1.0, 3.1) | 2.1 (1.4, 3.0) | 1.0 (0.4, 1.6) | 2.6 (1.6, 5.0) | 1.5 (1.0, 2.0) | 3.5 (2.1, 5.0) | | Unknown | 5 | 1 | 0 | 2 | 0 | 0 | 2 | | Fruits (times/week) | 9.0 (5.9, 18.0) | 15.5 (10.0, 21.0) | 6.6 (3.3, 13.5) | 7.3 (3.8, 9.6) | 14.1 (8.6, 21.0) | 8.5 (6.2, 13.5) | 7.5 (3.6, 12.6) | | Unknown | 7 | 2 | 0 | 2 | 1 | 0 | 2 | | Vegetables (times/week) | 6.5 (4.0, 10.0) | 6.0 (4.0, 10.0) | 8.3 (4.4, 11.0) | 6.0 (3.5, 8.5) | 8.5 (6.0, 14.0) | 6.5 (4.0, 10.0) | 6.0 (3.0, 8.5) | | Unknown | 6 | 1 | 0 | 2 | 1 | 0 | 2 | | Tobacco consumption |  |  |  |  |  |  |  | | Non-smoker and has never smoked | 681.0 (52.6%) | 148.0 (72.5%) | 87.0 (43.9%) | 104.0 (51.7%) | 138.0 (50.7%) | 101.0 (50.8%) | 103.0 (46.8%) | | Non-smoker but previously smoked although not daily | 163.0 (12.6%) | 12.0 (5.9%) | 19.0 (9.6%) | 32.0 (15.9%) | 63.0 (23.2%) | 14.0 (7.0%) | 23.0 (10.5%) | | Non-smoker but previously smoked daily | 186.0 (14.4%) | 11.0 (5.4%) | 37.0 (18.7%) | 21.0 (10.4%) | 53.0 (19.5%) | 22.0 (11.1%) | 42.0 (19.1%) | | Smoker but not daily | 64.0 (4.9%) | 6.0 (2.9%) | 10.0 (5.1%) | 20.0 (10.0%) | 12.0 (4.4%) | 9.0 (4.5%) | 7.0 (3.2%) | | Daily smoker | 200.0 (15.5%) | 27.0 (13.2%) | 45.0 (22.7%) | 24.0 (11.9%) | 6.0 (2.2%) | 53.0 (26.6%) | 45.0 (20.5%) | | Unknown | 3 | 0 | 0 | 2 | 0 | 0 | 1 | | Creatinine pooled sample (g/l) | 1.0 (0.8, 1.2) | 1.0 (0.8, 1.2) | 1.2 (1.0, 1.5) | 0.9 (0.7, 1.1) | 0.9 (0.7, 1.1) | 0.9 (0.7, 1.1) | 1.0 (0.8, 1.3) | | Mood before assessment |  |  |  |  |  |  |  | | Usual | 1,232.0 (95.1%) | 198.0 (97.1%) | 176.0 (89.3%) | 187.0 (92.1%) | 262.0 (96.3%) | 195.0 (98.0%) | 214.0 (96.8%) | | Not usual | 64.0 (4.9%) | 6.0 (2.9%) | 21.0 (10.7%) | 16.0 (7.9%) | 10.0 (3.7%) | 4.0 (2.0%) | 7.0 (3.2%) | | Unknown | 1 | 0 | 1 | 0 | 0 | 0 | 0 | | Rest before assessment |  |  |  |  |  |  |  | | Yes | 1,209.0 (93.3%) | 192.0 (94.1%) | 170.0 (86.3%) | 200.0 (98.5%) | 259.0 (95.2%) | 182.0 (91.5%) | 206.0 (93.2%) | | Not as well as usual | 87.0 (6.7%) | 12.0 (5.9%) | 27.0 (13.7%) | 3.0 (1.5%) | 13.0 (4.8%) | 17.0 (8.5%) | 15.0 (6.8%) | | Unknown | 1 | 0 | 1 | 0 | 0 | 0 | 0 | | Child ethnicity |  |  |  |  |  |  |  | | African | 7.0 (0.5%) | 7.0 (3.4%) | 0.0 (0.0%) | 0.0 (0.0%) | 0.0 (0.0%) | 0.0 (0.0%) | 0.0 (0.0%) | | Asian | 21.0 (1.6%) | 13.0 (6.4%) | 1.0 (0.5%) | 0.0 (0.0%) | 7.0 (2.6%) | 0.0 (0.0%) | 0.0 (0.0%) | | Caucasian | 1,157.0 (90.0%) | 87.0 (42.6%) | 196.0 (99.5%) | 200.0 (100.0%) | 254.0 (95.8%) | 199.0 (100.0%) | 221.0 (100.0%) | | Native American | 2.0 (0.2%) | 0.0 (0.0%) | 0.0 (0.0%) | 0.0 (0.0%) | 2.0 (0.8%) | 0.0 (0.0%) | 0.0 (0.0%) | | Other | 19.0 (1.5%) | 17.0 (8.3%) | 0.0 (0.0%) | 0.0 (0.0%) | 2.0 (0.8%) | 0.0 (0.0%) | 0.0 (0.0%) | | Pakistani | 80.0 (6.2%) | 80.0 (39.2%) | 0.0 (0.0%) | 0.0 (0.0%) | 0.0 (0.0%) | 0.0 (0.0%) | 0.0 (0.0%) | | White non European | 0.0 (0.0%) | 0.0 (0.0%) | 0.0 (0.0%) | 0.0 (0.0%) | 0.0 (0.0%) | 0.0 (0.0%) | 0.0 (0.0%) | | Unknown | 11 | 0 | 1 | 3 | 7 | 0 | 0 | | Family affluence scale |  |  |  |  |  |  |  | | 0 | 6.0 (0.5%) | 2.0 (1.0%) | 0.0 (0.0%) | 1.0 (0.5%) | 0.0 (0.0%) | 2.0 (1.0%) | 1.0 (0.5%) | | 1 | 12.0 (0.9%) | 4.0 (2.0%) | 0.0 (0.0%) | 4.0 (2.0%) | 1.0 (0.4%) | 1.0 (0.5%) | 2.0 (0.9%) | | 2 | 28.0 (2.2%) | 16.0 (7.8%) | 0.0 (0.0%) | 4.0 (2.0%) | 0.0 (0.0%) | 7.0 (3.5%) | 1.0 (0.5%) | | 3 | 92.0 (7.1%) | 34.0 (16.7%) | 2.0 (1.0%) | 22.0 (10.9%) | 3.0 (1.1%) | 20.0 (10.1%) | 11.0 (5.0%) | | 4 | 174.0 (13.4%) | 40.0 (19.6%) | 13.0 (6.6%) | 38.0 (18.8%) | 16.0 (5.9%) | 45.0 (22.6%) | 22.0 (10.0%) | | 5 | 325.0 (25.1%) | 48.0 (23.5%) | 29.0 (14.6%) | 69.0 (34.2%) | 57.0 (21.0%) | 57.0 (28.6%) | 65.0 (29.5%) | | 6 | 410.0 (31.7%) | 34.0 (16.7%) | 64.0 (32.3%) | 50.0 (24.8%) | 142.0 (52.2%) | 45.0 (22.6%) | 75.0 (34.1%) | | 7 | 248.0 (19.2%) | 26.0 (12.7%) | 90.0 (45.5%) | 14.0 (6.9%) | 53.0 (19.5%) | 22.0 (11.1%) | 43.0 (19.5%) | | Unknown | 2 | 0 | 0 | 1 | 0 | 0 | 1 | | Financial situation |  |  |  |  |  |  |  | | Living comfortably | 412.0 (31.9%) | 59.0 (28.9%) | 49.0 (24.7%) | 48.0 (24.0%) | 202.0 (74.3%) | 25.0 (12.6%) | 29.0 (13.2%) | | Doing alright | 414.0 (32.1%) | 73.0 (35.8%) | 94.0 (47.5%) | 61.0 (30.5%) | 64.0 (23.5%) | 58.0 (29.3%) | 64.0 (29.2%) | | Getting by | 331.0 (25.6%) | 59.0 (28.9%) | 36.0 (18.2%) | 70.0 (35.0%) | 4.0 (1.5%) | 80.0 (40.4%) | 82.0 (37.4%) | | Finding it quite difficult | 86.0 (6.7%) | 8.0 (3.9%) | 9.0 (4.5%) | 12.0 (6.0%) | 1.0 (0.4%) | 27.0 (13.6%) | 29.0 (13.2%) | | Finding it very difficult | 40.0 (3.1%) | 5.0 (2.5%) | 10.0 (5.1%) | 2.0 (1.0%) | 0.0 (0.0%) | 8.0 (4.0%) | 15.0 (6.8%) | | Does not wish to answer | 8.0 (0.6%) | 0.0 (0.0%) | 0.0 (0.0%) | 7.0 (3.5%) | 1.0 (0.4%) | 0.0 (0.0%) | 0.0 (0.0%) | | Unknown | 6 | 0 | 0 | 3 | 0 | 1 | 2 | | Marital status |  |  |  |  |  |  |  | | Living with the father | 39.0 (3.0%) | 0.0 (0.0%) | 2.0 (1.0%) | 31.0 (15.6%) | 3.0 (1.1%) | 3.0 (1.5%) | 0.0 (0.0%) | | Living alone | 1,212.0 (94.5%) | 178.0 (87.3%) | 193.0 (98.0%) | 168.0 (84.4%) | 260.0 (98.5%) | 194.0 (98.5%) | 219.0 (99.1%) | | Other situation | 31.0 (2.4%) | 26.0 (12.7%) | 2.0 (1.0%) | 0.0 (0.0%) | 1.0 (0.4%) | 0.0 (0.0%) | 2.0 (0.9%) | | Unknown | 15 | 0 | 1 | 4 | 8 | 2 | 0 | | Pregnancy maternal active smoking | 190.0 (15.1%) | 25.0 (13.7%) | 47.0 (23.7%) | 12.0 (6.0%) | 9.0 (3.4%) | 42.0 (21.2%) | 55.0 (25.1%) | | Unknown | 40 | 22 | 0 | 4 | 11 | 1 | 2 | | Pregnancy maternal passive smoking | 514.0 (40.3%) | 55.0 (27.5%) | 43.0 (21.8%) | 97.0 (48.7%) | 14.0 (5.3%) | 179.0 (90.4%) | 126.0 (57.8%) | | Unknown | 21 | 4 | 1 | 4 | 8 | 1 | 3 | | Child neuropsychological diagnosis | 95.0 (7.3%) | 3.0 (1.5%) | 58.0 (29.3%) | 1.0 (0.5%) | 1.0 (0.4%) | 8.0 (4.0%) | 24.0 (10.9%) | | Date of test (season) |  |  |  |  |  |  |  | | autumn | 300.0 (23.2%) | 49.0 (24.0%) | 1.0 (0.5%) | 77.0 (37.9%) | 105.0 (38.6%) | 38.0 (19.2%) | 30.0 (13.7%) | | spring | 358.0 (27.7%) | 48.0 (23.5%) | 64.0 (32.3%) | 61.0 (30.0%) | 37.0 (13.6%) | 77.0 (38.9%) | 71.0 (32.4%) | | summer | 297.0 (23.0%) | 67.0 (32.8%) | 72.0 (36.4%) | 27.0 (13.3%) | 57.0 (21.0%) | 53.0 (26.8%) | 21.0 (9.6%) | | winter | 339.0 (26.2%) | 40.0 (19.6%) | 61.0 (30.8%) | 38.0 (18.7%) | 73.0 (26.8%) | 30.0 (15.2%) | 97.0 (44.3%) | | Unknown | 3 | 0 | 0 | 0 | 0 | 1 | 2 | | Sex |  |  |  |  |  |  |  | | Male | 587.0 (45.3%) | 92.0 (45.1%) | 85.0 (42.9%) | 92.0 (45.3%) | 129.0 (47.4%) | 88.0 (44.2%) | 101.0 (45.7%) | | Female | 710.0 (54.7%) | 112.0 (54.9%) | 113.0 (57.1%) | 111.0 (54.7%) | 143.0 (52.6%) | 111.0 (55.8%) | 120.0 (54.3%) | | Fasting time | 3.3 (2.8, 4.0) | 3.3 (2.8, 4.1) | 3.2 (2.8, 3.7) | 3.3 (2.8, 3.8) | 3.4 (2.8, 3.8) | 4.0 (3.3, 4.8) | 3.0 (2.6, 3.8) | | Creatinine night sample (g/l) | 1.7 (0.9, 3.0) | 0.8 (0.6, 1.1) | 3.3 (2.0, 4.3) | 1.7 (0.9, 2.7) | 2.0 (1.2, 3.0) | 0.8 (0.4, 1.3) | 2.5 (1.5, 3.8) | | Unknown | 321 | 72 | 64 | 23 | 72 | 71 | 19 | | *a*Median (IQR); n (%) | | | | | | | |   Table S1: **Participant characteristics, by cohort and overall (HELIX subcohort; 2013-2016).** |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  | type | description | coding | labels | remarks | comments | included*a* | | --- | --- | --- | --- | --- | --- | --- | --- | | **age\_child** | | | | | | | | | hs\_age\_years | numerical | Age of the child at clinical assessment |  |  |  | years | TRUE | | **breastfeeding** | | | | | | | | | hs\_bf | categorical | Child breastfeeding | 0,1 | No, Yes |  |  | TRUE | | **characteristics\_child** | | | | | | | | | hs\_c\_height | numerical | Height of the child |  |  |  | m | TRUE | | hs\_c\_weight | numerical | Weight of the child |  |  |  | kg | TRUE | | hs\_head\_circ | numerical | Head circumference of the child |  |  |  | cm | TRUE | | **child\_diet** | | | | | | | | | hs\_fastfood | numerical | Visits a fast food restaurant/take away |  |  |  | Times / week | TRUE | | hs\_org\_food | numerical | Eats organic food |  |  |  | Times / week | TRUE | | hs\_total\_fish | numerical | Food group: fish and seafood (hs\_canfish+hs\_oilyfish+hs\_whfish+hs\_seafood) |  |  |  | Times / week | TRUE | | hs\_total\_fruits | numerical | Food group: fruits (hs\_canfruit+hs\_dryfruit+hs\_freshjuice+hs\_fruits) |  |  |  | Times / week | TRUE | | hs\_total\_veg | numerical | Food group: vegetables (hs\_cookveg+hs\_rawveg) |  |  |  | Times / week | TRUE | | **child\_smoking** | | | | | | | | | hs\_tob | categorical | Which of the following best describes your consumption of tobacco? | 1,2,3,4,5 | Non-smoker and has never smoked, Non-smoker but previously smoked although not daily, Non-smoker but previously smoked daily, Smoker but not daily, Daily smoker |  |  | TRUE | | **cohort** | | | | | | | | | cohort | character | Cohort name | SAB,EDEN,BIB,RHEA,KANC,MOBA | SAB, EDEN, BIB, RHEA, KANC, MOBA |  |  | TRUE | | **creatinine** | | | | | | | | | hs\_creatinine\_cg | numerical | Creatinine in child in pooled sample |  |  | Values below the limit of detection imputed | G / L | TRUE | | **envFactors\_visit** | | | | | | | | | hs\_mood | categorical | Mood of the child in the last few days before assessment | 1,2 | Usual, Not usual |  |  | TRUE | | hs\_rest\_nth | categorical | Child rested the night before assessment | 1,2 | Yes, Not as well as usual |  |  | TRUE | | **ethnicity\_child** | | | | | | | | | h\_ethnicity\_c | character | Which is the ethnicity of the child? | 1,2,3,4,5,6,7 | African, Asian, Caucasian, Native American, Other, Pakistani, White non European |  |  | TRUE | | **ethnicity\_mother** | | | | | | | | | h\_ethnicity\_m | integer | Which is the ethnicity of the mother? | 1,2,3,4,5,6,7 | White European, Pakistani, Asian, African, Other, Native American, White non European |  |  | FALSE | | **familySEP** | | | | | | | | | FAS\_score | numerical | Family Affluence Scale (FAS II) continuous |  |  |  |  | TRUE | | hs\_finance | categorical | How well would you say your family is managing financially these days? | 1,2,3,4,5,6 | Living comfortably, Doing alright, Getting by, Finding it quite difficult, Finding it very difficult, Does not wish to answer |  |  | TRUE | | **maternalAlcohol\_preg** | | | | | | | | | e3\_alcpreg\_g | numerical | Alcool during pregnancy |  |  |  | Glasses / week | FALSE | | **maternalDiet\_preg** | | | | | | | | | h\_cereal\_preg | numerical | Cereal consumption during pregnancy |  |  |  | Times / week | FALSE | | h\_dairy\_preg | numerical | Dairy consumption during pregnancy |  |  |  | Times / week | FALSE | | h\_fastfood\_preg | numerical | Fast food consumption during pregnancy |  |  |  | Times / week | FALSE | | h\_fish\_preg | numerical | Fish consumption during pregnancy |  |  |  | Times / week | FALSE | | h\_fruit\_preg | numerical | Fruit consumption during pregnancy |  |  |  | Times / week | FALSE | | h\_legume\_preg | numerical | Legume consumption during pregnancy |  |  |  | Times / week | FALSE | | h\_meat\_preg | numerical | Meat consumption during pregnancy |  |  |  | Times / week | FALSE | | h\_veg\_preg | numerical | Vegetables consumption during pregnancy |  |  |  | Times / week | FALSE | | **maternalSEP\_preg** | | | | | | | | | e3\_edum | categorical | Maternal education | 0,1,2 | Primary school, Secondary school, University degree or higher |  |  | FALSE | | e3\_marital | categorical | Marital status | 0,1,2 | Living with the father, Living alone, Other situation |  |  | TRUE | | e3\_ses | categorical | Socioeconomic status of the parents | 1,2,3 | Low income, Medium income, High income |  |  | FALSE | | **maternalSmoking\_preg** | | | | | | | | | e3\_asmokyn\_p | categorical | Maternal active smoking during pregnancy | 0,1 | No, Yes |  |  | TRUE | | e3\_psmokanyt | categorical | Maternal passive smoking during pregnancy | 0,1 | No, Yes |  |  | TRUE | | **neuropsychologicalDiagnosis\_child** | | | | | | | | | hs\_neuro\_diag | categorical | Any previous child neuropsychological diagnosis? | 1,2 | No, Yes |  |  | TRUE | | **paternalSEP\_preg** | | | | | | | | | e3\_eduf | categorical | Paternal education | 0,1,2 | Primary school, Secondary school, University degree or higher |  |  | FALSE | | **season\_visit** | | | | | | | | | hs\_date\_neu | date | Date of test |  |  |  | season | TRUE | | **sex\_child** | | | | | | | | | e3\_sex | categorical | Child’s sex | 0,1 | Male, Female |  |  | TRUE | | **time\_lastMeal** | | | | | | | | | hs\_dift\_mealblood\_imp | numerical | Imputed difference between blood time extraction and last meal time |  |  |  |  | TRUE | | *a*Percentage of confounders included in the models: 65.79%. | | | | | | | |   Table S2: **Codebook for the covariates used in the estimation of the marginal comparisons of EDCs on HRT-SE.** |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  | type | description | coding | labels | remarks | comments | included*a* | | --- | --- | --- | --- | --- | --- | --- | --- | | **age\_child** | | | | | | | | | hs\_age\_years | numerical | Age of the child at clinical assessment |  |  |  | years | TRUE | | **characteristics\_child** | | | | | | | | | hs\_c\_height | numerical | Height of the child |  |  |  | m | TRUE | | hs\_c\_weight | numerical | Weight of the child |  |  |  | kg | TRUE | | hs\_head\_circ | numerical | Head circumference of the child |  |  |  | cm | TRUE | | **child\_diet** | | | | | | | | | hs\_fastfood | numerical | Visits a fast food restaurant/take away |  |  |  | Times / week | TRUE | | hs\_org\_food | numerical | Eats organic food |  |  |  | Times / week | TRUE | | hs\_total\_fish | numerical | Food group: fish and seafood (hs\_canfish+hs\_oilyfish+hs\_whfish+hs\_seafood) |  |  |  | Times / week | TRUE | | hs\_total\_fruits | numerical | Food group: fruits (hs\_canfruit+hs\_dryfruit+hs\_freshjuice+hs\_fruits) |  |  |  | Times / week | TRUE | | hs\_total\_veg | numerical | Food group: vegetables (hs\_cookveg+hs\_rawveg) |  |  |  | Times / week | TRUE | | **child\_smoking** | | | | | | | | | hs\_tob | categorical | Which of the following best describes your consumption of tobacco? | 1,2,3,4,5 | Non-smoker and has never smoked, Non-smoker but previously smoked although not daily, Non-smoker but previously smoked daily, Smoker but not daily, Daily smoker |  |  | TRUE | | **cohort** | | | | | | | | | cohort | character | Cohort name | SAB,EDEN,BIB,RHEA,KANC,MOBA | SAB, EDEN, BIB, RHEA, KANC, MOBA |  |  | TRUE | | **creatinine** | | | | | | | | | creatinine\_to\_helix | numerical | Creatinine in child in night sample |  |  |  | G / L | TRUE | | hs\_creatinine\_cg | numerical | Creatinine in child in pooled sample |  |  | Values below the limit of detection imputed | G / L | TRUE | | **ethnicity\_child** | | | | | | | | | h\_ethnicity\_c | character | Which is the ethnicity of the child? | 1,2,3,4,5,6,7 | African, Asian, Caucasian, Native American, Other, Pakistani, White non European |  |  | TRUE | | **ethnicity\_mother** | | | | | | | | | h\_ethnicity\_m | integer | Which is the ethnicity of the mother? | 1,2,3,4,5,6,7 | White European, Pakistani, Asian, African, Other, Native American, White non European |  |  | FALSE | | **familySEP** | | | | | | | | | FAS\_score | numerical | Family Affluence Scale (FAS II) continuous |  |  |  |  | TRUE | | hs\_finance | categorical | How well would you say your family is managing financially these days? | 1,2,3,4,5,6 | Living comfortably, Doing alright, Getting by, Finding it quite difficult, Finding it very difficult, Does not wish to answer |  |  | TRUE | | **season\_visit** | | | | | | | | | hs\_date\_neu | date | Date of test |  |  |  | season | TRUE | | **sex\_child** | | | | | | | | | e3\_sex | categorical | Child’s sex | 0,1 | Male, Female |  |  | TRUE | | **time\_lastMeal** | | | | | | | | | hs\_dift\_mealblood\_imp | numerical | Imputed difference between blood time extraction and last meal time |  |  |  |  | TRUE | | *a*Percentage of confounders included in the models: 95%. | | | | | | | |   Table S3: **Codebook for the covariates used in the estimation of the marginal comparisons of EDCs on the glucocorticosteroids.** |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  | type | description | coding | labels | remarks | comments | included*a* | | --- | --- | --- | --- | --- | --- | --- | --- | | **age\_child** | | | | | | | | | hs\_age\_years | numerical | Age of the child at clinical assessment |  |  |  | years | TRUE | | **breastfeeding** | | | | | | | | | hs\_bf | categorical | Child breastfeeding | 0,1 | No, Yes |  |  | TRUE | | **characteristics\_child** | | | | | | | | | hs\_c\_height | numerical | Height of the child |  |  |  | m | TRUE | | hs\_c\_weight | numerical | Weight of the child |  |  |  | kg | TRUE | | hs\_head\_circ | numerical | Head circumference of the child |  |  |  | cm | TRUE | | **chemical** | | | | | | | | | hs\_bpa\_c | numerical | Bisphenol A (BPA) |  |  | Values below the limit of detection imputed | microg / L | TRUE | | hs\_bupa\_c | numerical | N-Butyl paraben (BUPA) |  |  | Values below the limit of detection imputed | microg / L | TRUE | | hs\_dedtp\_cadj | numerical | Diethyl dithiophosphate (DEDTP) adjusted for creatinine |  |  | Values below the limit of detection imputed | microg / g | FALSE | | hs\_dep\_c | numerical | Diethyl phosphate (DEP) |  |  | Values below the limit of detection imputed | microg / L | TRUE | | hs\_detp\_c | numerical | Diethyl thiophosphate (DETP) |  |  | Values below the limit of detection imputed | microg / L | TRUE | | hs\_dmdtp\_craw | numerical | Dimethyl dithiophosphate (DMDTP) |  |  | Values below the limit of detection imputed | microg / L | FALSE | | hs\_dmp\_c | numerical | Dimethyl phosphate (DMP) |  |  | Values below the limit of detection imputed | microg / L | TRUE | | hs\_dmtp\_c | numerical | Dimethyl thiophosphate (DMTP) |  |  | Values below the limit of detection imputed | microg / L | TRUE | | hs\_etpa\_c | numerical | Ethyl paraben (ETPA) |  |  | Values below the limit of detection imputed | microg / L | TRUE | | hs\_mbzp\_c | numerical | Mono benzyl phthalate (MbzP) |  |  | Values below the limit of detection imputed | microg / L | TRUE | | hs\_mecpp\_c | numerical | Mono-2-ethyl 5-carboxypentyl phthalate (MECPP) |  |  | Values below the limit of detection imputed | microg / L | TRUE | | hs\_mehhp\_c | numerical | Mono-2-ethyl-5-hydroxyhexyl phthalate (MEHHP) |  |  | Values below the limit of detection imputed | microg / L | TRUE | | hs\_mehp\_c | numerical | Mono-2-ethylhexyl phthalate (MEHP) |  |  | Values below the limit of detection imputed | microg / L | TRUE | | hs\_meohp\_c | numerical | Mono-2-ethyl-5-oxohexyl phthalate (MEOHP) |  |  | Values below the limit of detection imputed | microg / L | TRUE | | hs\_mep\_c | numerical | Monoethyl phthalate (MEP) |  |  | Values below the limit of detection imputed | microg / L | TRUE | | hs\_mepa\_c | numerical | Methyl paraben (MEPA) |  |  | Values below the limit of detection imputed | microg / L | TRUE | | hs\_mibp\_c | numerical | Mono-iso-butyl phthalate (MiBP) |  |  | Values below the limit of detection imputed | microg / L | TRUE | | hs\_mnbp\_c | numerical | Mono-n-butyl phthalate (MnBP) |  |  | Values below the limit of detection imputed | microg / L | TRUE | | hs\_ohminp\_c | numerical | Mono-4-methyl-7-hydroxyoctyl phthalate (OHMiNP) |  |  | Values below the limit of detection imputed | microg / L | TRUE | | hs\_oxbe\_c | numerical | Oxybenzone (OXBE) |  |  | Values below the limit of detection imputed | microg / L | TRUE | | hs\_oxominp\_c | numerical | Mono-4-methyl-7-oxooctyl phthalate (OXOMiNP) |  |  | Values below the limit of detection imputed | microg / L | TRUE | | hs\_prpa\_c | numerical | Propyl paraben (PRPA) |  |  | Values below the limit of detection imputed | microg / L | TRUE | | hs\_trcs\_c | numerical | Triclosan (TRCS) |  |  | Values below the limit of detection imputed | microg / L | TRUE | | **child\_diet** | | | | | | | | | hs\_fastfood | numerical | Visits a fast food restaurant/take away |  |  |  | Times / week | TRUE | | hs\_org\_food | numerical | Eats organic food |  |  |  | Times / week | TRUE | | hs\_total\_fish | numerical | Food group: fish and seafood (hs\_canfish+hs\_oilyfish+hs\_whfish+hs\_seafood) |  |  |  | Times / week | TRUE | | hs\_total\_fruits | numerical | Food group: fruits (hs\_canfruit+hs\_dryfruit+hs\_freshjuice+hs\_fruits) |  |  |  | Times / week | TRUE | | hs\_total\_veg | numerical | Food group: vegetables (hs\_cookveg+hs\_rawveg) |  |  |  | Times / week | TRUE | | **child\_smoking** | | | | | | | | | hs\_tob | categorical | Which of the following best describes your consumption of tobacco? | 1,2,3,4,5 | Non-smoker and has never smoked, Non-smoker but previously smoked although not daily, Non-smoker but previously smoked daily, Smoker but not daily, Daily smoker |  |  | TRUE | | **cohort** | | | | | | | | | cohort | character | Cohort name | SAB,EDEN,BIB,RHEA,KANC,MOBA | SAB, EDEN, BIB, RHEA, KANC, MOBA |  |  | TRUE | | **creatinine** | | | | | | | | | creatinine\_to\_helix | numerical | Creatinine in child in night sample |  |  |  | G / L | TRUE | | **envFactors\_visit** | | | | | | | | | hs\_mood | categorical | Mood of the child in the last few days before assessment | 1,2 | Usual, Not usual |  |  | TRUE | | hs\_rest\_nth | categorical | Child rested the night before assessment | 1,2 | Yes, Not as well as usual |  |  | TRUE | | **ethnicity\_child** | | | | | | | | | h\_ethnicity\_c | character | Which is the ethnicity of the child? | 1,2,3,4,5,6,7 | African, Asian, Caucasian, Native American, Other, Pakistani, White non European |  |  | TRUE | | **ethnicity\_mother** | | | | | | | | | h\_ethnicity\_m | integer | Which is the ethnicity of the mother? | 1,2,3,4,5,6,7 | White European, Pakistani, Asian, African, Other, Native American, White non European |  |  | FALSE | | **familySEP** | | | | | | | | | FAS\_score | numerical | Family Affluence Scale (FAS II) continuous |  |  |  |  | TRUE | | hs\_finance | categorical | How well would you say your family is managing financially these days? | 1,2,3,4,5,6 | Living comfortably, Doing alright, Getting by, Finding it quite difficult, Finding it very difficult, Does not wish to answer |  |  | TRUE | | **maternalAlcohol\_preg** | | | | | | | | | e3\_alcpreg\_g | numerical | Alcool during pregnancy |  |  |  | Glasses / week | FALSE | | **maternalDiet\_preg** | | | | | | | | | h\_cereal\_preg | numerical | Cereal consumption during pregnancy |  |  |  | Times / week | FALSE | | h\_dairy\_preg | numerical | Dairy consumption during pregnancy |  |  |  | Times / week | FALSE | | h\_fastfood\_preg | numerical | Fast food consumption during pregnancy |  |  |  | Times / week | FALSE | | h\_fish\_preg | numerical | Fish consumption during pregnancy |  |  |  | Times / week | FALSE | | h\_fruit\_preg | numerical | Fruit consumption during pregnancy |  |  |  | Times / week | FALSE | | h\_legume\_preg | numerical | Legume consumption during pregnancy |  |  |  | Times / week | FALSE | | h\_meat\_preg | numerical | Meat consumption during pregnancy |  |  |  | Times / week | FALSE | | h\_veg\_preg | numerical | Vegetables consumption during pregnancy |  |  |  | Times / week | FALSE | | **maternalSEP\_preg** | | | | | | | | | e3\_edum | categorical | Maternal education | 0,1,2 | Primary school, Secondary school, University degree or higher |  |  | FALSE | | e3\_marital | categorical | Marital status | 0,1,2 | Living with the father, Living alone, Other situation |  |  | TRUE | | e3\_ses | categorical | Socioeconomic status of the parents | 1,2,3 | Low income, Medium income, High income |  |  | FALSE | | **maternalSmoking\_preg** | | | | | | | | | e3\_asmokyn\_p | categorical | Maternal active smoking during pregnancy | 0,1 | No, Yes |  |  | TRUE | | e3\_psmokanyt | categorical | Maternal passive smoking during pregnancy | 0,1 | No, Yes |  |  | TRUE | | **neuropsychologicalDiagnosis\_child** | | | | | | | | | hs\_neuro\_diag | categorical | Any previous child neuropsychological diagnosis? | 1,2 | No, Yes |  |  | TRUE | | **paternalSEP\_preg** | | | | | | | | | e3\_eduf | categorical | Paternal education | 0,1,2 | Primary school, Secondary school, University degree or higher |  |  | FALSE | | **sex\_child** | | | | | | | | | e3\_sex | categorical | Child’s sex | 0,1 | Male, Female |  |  | TRUE | | *a*Percentage of confounders included in the models: 74.58%. | | | | | | | |   Table S4: **Codebook for the covariates used in the estimation of the marginal comparisons of the glucocorticosteroids on HRT-SE.** |

### Description of endocrine disruptors

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| | Compound | Symbol | Variable name | PubChem CID | Parental compound | | --- | --- | --- | --- | --- | | **OP pesticide metabolites** | | | | | | diethyl dithiophosphate | DEDTP | dedtp | 9274 |  | | diethyl phosphate | DEP | dep | 654 |  | | diethyl thiophosphate | DETP | detp | 3683036 |  | | dimethyl dithiophosphate | DMDTP | dmdtp |  |  | | dimethyl phosphate | DMP | dmp | 13134 |  | | dimethyl thiophosphate | DMTP | dmtp | 168140 |  | | **Phenols** | | | | | | bisphenol A | BPA | bpa | 6623 |  | | ethyl-paraben | ETPA | etpa | 8434 |  | | methyl-paraben | MEPA | mepa | 7456 |  | | n‑butyl‑paraben | BUPA | bupa | 7184 |  | | oxybenzone | OXBE | oxbe | 4632 |  | | propyl-paraben | PRPA | prpa | 7175 |  | | triclosan | TRCS | trcs | 5564 |  | | **Phthalate metabolites** | | | | | | mono benzyl phthalate | MBzP | mbzp | 31736 | BBzP | | mono‑2‑ethyl 5‑carboxypentyl phthalate | MECPP | mecpp | 148386 | DEHP | | mono‑2‑ethyl‑5‑hydroxyhexyl phthalate | MEHHP | mehhp | 170295 | DEHP | | mono‑2‑ethyl‑5‑oxohexyl phthalate | MEOHP | meohp | 119096 | DEHP | | mono‑2‑ethylhexyl phthalate | MEHP | mehp | 21924291 | DEHP | | mono‑4‑methyl‑7‑hydroxyoctyl phthalate | oh-MiNP | ohminp | 102401880 | MiNP | | mono‑4‑methyl‑7‑oxooctyl phthalate | oxo-MiNP | oxominp | 102401881 | MiNP | | mono‑iso‑butyl phthalate | MiBP | mibp | 92272 | DiBP | | mono‑n‑butyl phthalate | MnBP | mnbp | 8575 | DnBP | | monoethyl phthalate | MEP | mep | 75318 | DEP |   Table S5: **Information about non-persistent EDCs, including the full compound name, the standard symbol, the used variable name, the identifier from PubChem, and the parental compound.** |

### Description of glucocorticosteroids

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| | **Characteristic** | **Overall**, N = 1,004*a* | **BIB**, N = 154*a* | **EDEN**, N = 137*a* | **KANC**, N = 180*a* | **MOBA**, N = 200*a* | **RHEA**, N = 128*a* | **SAB**, N = 205*a* | | --- | --- | --- | --- | --- | --- | --- | --- | | **Glucocorticosteroid** | | | | | | | | | F | 5.5 (3.2, 9.5) | 6.3 (4.2, 10.4) | 7.8 (4.2, 11.4) | 4.9 (2.7, 8.2) | 5.2 (3.0, 9.1) | 6.2 (3.4, 13.1) | 4.6 (2.9, 7.1) | | Unknown | 2 | 0 | 0 | 1 | 1 | 0 | 0 | | E | 22.9 (13.1, 38.5) | 25.7 (14.5, 41.4) | 28.6 (14.1, 42.0) | 21.4 (12.0, 33.7) | 23.3 (14.1, 38.1) | 28.9 (19.3, 59.4) | 17.1 (10.3, 27.4) | | A | 4.3 (2.4, 8.2) | 4.8 (2.8, 9.0) | 5.1 (2.6, 9.1) | 3.8 (2.0, 7.3) | 4.3 (2.7, 8.4) | 5.9 (3.5, 14.9) | 3.0 (1.6, 5.6) | | Unknown | 1 | 0 | 0 | 0 | 0 | 0 | 1 | | **Glucocorticosteroid metabolite** | | | | | | | | | 20aDHF | 6.6 (3.3, 13.3) | 7.2 (3.8, 14.0) | 10.0 (5.7, 19.5) | 4.8 (2.2, 11.4) | 7.4 (4.2, 14.0) | 6.5 (2.9, 13.8) | 5.5 (3.0, 9.4) | | Unknown | 7 | 4 | 0 | 3 | 0 | 0 | 0 | | 20bDHF | 15.2 (9.1, 24.8) | 16.5 (10.8, 26.5) | 19.9 (12.0, 32.0) | 14.0 (8.5, 24.5) | 14.2 (8.4, 23.5) | 14.3 (7.9, 27.5) | 13.0 (8.0, 18.1) | | 5bDHF | 1.4 (0.9, 2.0) | 1.4 (0.9, 2.2) | 1.8 (1.3, 2.6) | 1.5 (1.1, 1.9) | 1.1 (0.6, 1.7) | 1.5 (1.0, 2.1) | 1.1 (0.6, 1.8) | | Unknown | 2 | 0 | 0 | 0 | 1 | 0 | 1 | | 5aTHF | 2,870.0 (1,663.7, 4,389.0) | 3,394.6 (2,288.1, 5,308.1) | 3,474.2 (1,856.1, 5,253.4) | 2,907.3 (1,656.1, 4,621.2) | 2,283.3 (1,259.8, 3,454.6) | 3,001.9 (1,652.3, 4,613.6) | 2,756.9 (1,565.6, 3,758.3) | | 5bTHF | 906.5 (548.0, 1,416.1) | 1,116.2 (660.8, 1,644.8) | 1,238.6 (743.1, 1,578.3) | 753.9 (389.4, 1,258.7) | 859.7 (492.9, 1,261.3) | 881.5 (565.0, 1,441.1) | 882.9 (542.6, 1,199.8) | | Unknown | 2 | 2 | 0 | 0 | 0 | 0 | 0 | | 6OHF | 42.8 (22.5, 76.7) | 51.9 (29.8, 93.9) | 55.8 (29.8, 82.3) | 36.6 (19.7, 68.7) | 46.0 (27.9, 82.9) | 42.0 (21.1, 93.2) | 32.3 (18.5, 53.3) | | 5a20acortol | 88.9 (52.1, 141.6) | 109.8 (61.7, 177.3) | 103.0 (58.0, 153.8) | 84.7 (46.9, 145.9) | 88.6 (53.7, 138.2) | 72.4 (47.2, 130.2) | 83.0 (45.9, 118.7) | | Unknown | 9 | 9 | 0 | 0 | 0 | 0 | 0 | | 5a20bcortol | 122.4 (70.4, 185.0) | 131.0 (66.3, 182.3) | 148.8 (108.8, 226.1) | 115.2 (62.9, 189.2) | 114.7 (67.8, 172.7) | 105.3 (72.6, 175.0) | 124.3 (68.9, 178.8) | | Unknown | 5 | 5 | 0 | 0 | 0 | 0 | 0 | | 5b20acortol | 147.7 (83.5, 225.8) | 177.4 (98.9, 302.3) | 169.7 (91.1, 252.9) | 143.0 (80.2, 229.8) | 143.7 (86.6, 204.2) | 137.7 (79.6, 220.5) | 141.9 (76.6, 187.6) | | Unknown | 11 | 11 | 0 | 0 | 0 | 0 | 0 | | 5b20bcortol | 195.7 (120.1, 302.4) | 242.7 (152.0, 356.8) | 225.2 (142.1, 371.5) | 155.8 (88.0, 270.4) | 186.3 (115.5, 269.4) | 177.5 (113.7, 301.7) | 199.9 (130.5, 289.3) | | Unknown | 3 | 3 | 0 | 0 | 0 | 0 | 0 | | 11OHAndros | 234.2 (130.3, 390.5) | 259.7 (151.9, 375.0) | 413.0 (221.7, 617.0) | 163.3 (80.7, 298.5) | 254.4 (151.5, 408.4) | 165.4 (95.9, 304.2) | 256.7 (142.9, 365.1) | | Unknown | 3 | 0 | 0 | 3 | 0 | 0 | 0 | | 20aDHE | 16.6 (9.7, 27.5) | 14.2 (7.0, 25.8) | 25.8 (15.1, 37.8) | 14.8 (7.7, 25.6) | 17.5 (11.7, 26.1) | 14.8 (8.7, 27.6) | 15.6 (10.2, 23.0) | | Unknown | 11 | 7 | 0 | 4 | 0 | 0 | 0 | | 20bDHE | 9.5 (6.2, 14.3) | 8.7 (4.8, 14.8) | 13.2 (9.7, 17.3) | 8.9 (5.1, 13.7) | 9.0 (5.9, 14.3) | 8.7 (5.3, 15.2) | 9.0 (6.6, 11.7) | | Unknown | 17 | 14 | 0 | 3 | 0 | 0 | 0 | | 5aTHE | 73.9 (39.7, 124.0) | 82.0 (52.1, 145.7) | 83.9 (41.5, 132.7) | 71.3 (40.3, 121.7) | 64.5 (36.4, 103.9) | 107.9 (51.2, 183.2) | 62.2 (32.3, 97.3) | | Unknown | 1 | 0 | 0 | 0 | 0 | 1 | 0 | | 5bTHE | 3,138.3 (1,889.5, 4,694.0) | 3,552.8 (2,335.3, 4,797.4) | 3,649.6 (2,293.5, 5,317.1) | 2,754.6 (1,448.0, 3,989.3) | 3,070.1 (1,785.5, 4,637.7) | 3,541.6 (2,010.1, 5,901.3) | 2,911.6 (1,615.2, 4,050.7) | | 6OHE | 11.9 (6.5, 18.4) | 13.2 (7.6, 20.6) | 12.2 (6.1, 17.4) | 13.1 (7.1, 19.6) | 11.2 (6.4, 18.1) | 14.3 (8.7, 24.3) | 9.2 (5.3, 14.1) | | 5b20acortolone | 641.9 (366.0, 983.1) | 638.3 (385.0, 1,028.2) | 903.7 (574.5, 1,296.1) | 518.0 (261.2, 870.2) | 580.6 (318.0, 901.5) | 629.3 (400.9, 962.4) | 654.6 (398.7, 890.7) | | 5b20bcortolone | 546.9 (336.3, 837.1) | 561.3 (331.3, 889.9) | 682.3 (452.0, 1,031.1) | 505.0 (272.3, 769.3) | 496.1 (289.2, 761.3) | 563.5 (328.4, 881.5) | 534.1 (372.6, 792.7) | | 5aTHB | 133.1 (76.1, 222.4) | 159.8 (101.7, 241.3) | 144.2 (87.9, 255.3) | 148.0 (82.6, 245.6) | 106.1 (61.1, 184.9) | 139.9 (74.6, 260.5) | 115.7 (73.3, 171.7) | | 5bTHB | 49.3 (28.0, 82.7) | 53.3 (27.5, 98.3) | 60.9 (34.9, 94.5) | 43.8 (27.5, 89.7) | 40.0 (24.7, 65.7) | 53.5 (28.4, 76.7) | 50.0 (29.7, 73.1) | | Unknown | 1 | 0 | 0 | 1 | 0 | 0 | 0 | | 17-DO-cortolone | 57.5 (29.1, 101.7) | 56.1 (32.8, 100.6) | 76.5 (46.0, 137.6) | 43.7 (15.1, 93.4) | 56.4 (26.4, 92.0) | 51.2 (28.5, 94.3) | 61.3 (32.5, 102.1) | | Unknown | 2 | 0 | 0 | 1 | 0 | 1 | 0 | | **Glucocorticosteroid precursor** | | | | | | | | | S | 0.4 (0.3, 0.8) | 0.5 (0.3, 0.9) | 0.4 (0.3, 0.7) | 0.3 (0.2, 0.5) | 0.4 (0.3, 0.7) | 0.4 (0.2, 0.8) | 0.6 (0.4, 0.9) | | Unknown | 94 | 6 | 5 | 9 | 51 | 11 | 12 | | **Glucocorticosteroid precursor metabolite** | | | | | | | | | 5bDHS | 0.3 (0.2, 0.4) | 0.3 (0.2, 0.4) | 0.3 (0.2, 0.5) | 0.2 (0.2, 0.3) | 0.3 (0.2, 0.4) | 0.3 (0.2, 0.5) | 0.3 (0.2, 0.3) | | Unknown | 132 | 5 | 20 | 0 | 57 | 7 | 43 | | 5bTHS | 30.7 (18.5, 50.5) | 35.7 (20.7, 59.2) | 34.5 (19.8, 52.1) | 31.3 (18.6, 55.1) | 26.2 (14.2, 40.8) | 33.7 (20.0, 58.2) | 27.7 (17.6, 43.0) | | Unknown | 2 | 0 | 0 | 0 | 1 | 0 | 1 | | 17HP | 22.3 (15.1, 33.5) | 17.0 (11.1, 27.6) | 33.2 (23.5, 44.0) | 20.3 (10.8, 33.1) | 23.0 (17.5, 31.2) | 21.8 (15.7, 32.2) | 20.3 (13.2, 32.2) | | Unknown | 1 | 0 | 0 | 0 | 0 | 1 | 0 | | PT | 200.6 (112.8, 342.0) | 149.1 (87.6, 246.3) | 378.8 (230.8, 542.8) | 142.2 (82.4, 273.7) | 176.4 (112.9, 283.3) | 189.4 (104.9, 306.3) | 253.4 (150.0, 404.4) | | **Androgen** | | | | | | | | | T | 0.5 (0.3, 1.0) | 0.7 (0.5, 1.0) | 1.0 (0.5, 1.9) | 0.3 (0.2, 0.6) | 0.4 (0.3, 0.7) | 0.4 (0.3, 0.7) | 0.6 (0.3, 1.0) | | Unknown | 75 | 0 | 5 | 29 | 24 | 14 | 3 | | AED | 0.2 (0.2, 0.3) | 0.2 (0.2, 0.3) | 0.3 (0.2, 0.5) | 0.2 (0.1, 0.3) | 0.2 (0.1, 0.3) | 0.2 (0.1, 1.1) | 0.2 (0.1, 0.4) | | Unknown | 407 | 0 | 34 | 117 | 106 | 77 | 73 | | **Androgen metabolite** | | | | | | | | | Andros | 186.0 (78.1, 394.0) | 148.4 (72.0, 267.9) | 552.2 (308.7, 980.2) | 98.4 (39.6, 227.5) | 134.7 (63.4, 293.1) | 110.0 (61.6, 226.5) | 295.4 (129.1, 513.8) | | Unknown | 1 | 0 | 0 | 1 | 0 | 0 | 0 | | Etio | 110.9 (50.7, 237.8) | 75.1 (32.6, 151.0) | 369.7 (231.8, 561.0) | 74.8 (37.6, 122.6) | 91.4 (45.8, 184.0) | 76.2 (41.2, 147.0) | 169.7 (84.0, 306.1) | | Unknown | 1 | 0 | 0 | 1 | 0 | 0 | 0 | | *a*Median (IQR) | | | | | | | |   Table S6: **Participants glucocorticosteroids concentrations, by cohort and overall (HELIX subcohort; 2013-2016).** |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| | Metabolite | Symbol | HMDB ID | CAS number | | --- | --- | --- | --- | | **Glucocorticosteroid** | | | | | Cortisol | F | HMDB0000063 | 50-23-7 | | Cortisone | E | HMDB0002802 | 53-06-5 | | Corticosterone | B | HMDB0001547 | 50-22-6 | | 11-dehydrocorticosterone | A | HMDB0004029 | 72-23-1 | | **Glucocorticosteroid metabolite** | | | | | 20α-dihydrocortisol | 20aDHF | NA | NA | | 20β-dihydrocortisol | 20bDHF | NA | NA | | 5β-dihydrocortisol | 5bDHF | HMDB0003259 | 1482-50-4 | | 5α-tetrahydrocortisol | 5aTHF | HMDB0000526 | 302-91-0 | | 5β-tetrahydrocortisol | 5bTHF | HMDB0000949 | 1953-02-01 | | 5α,20α-cortol | 5a20acortol | HMDB0003180 | 516-38-1 | | 5α,20β-cortol | 5a20bcortol | HMDB0005821 | 667-65-2 | | 5β,20α-cortol | 5b20acortol | HMDB0003180 | 516-38-1 | | 5β,20β-cortol | 5b20bcortol | HMDB0005821 | 667-65-2 | | 6β-hydroxycortisol | 6OHF | HMDB0247074 |  | | 11β-hydroxyandrosterone | 11OHAndros | HMDB0002984 | 57-61-4 | | 20α-dihydrocortisone | 20aDHE | NA | NA | | 20β-dihydrocortisone | 20bDHE | NA | NA | | 5α-tetrahydrocortisone | 5aTHE | NA | NA | | 5β-tetrahydrocortisone | 5bTHE | NA | NA | | 5β,20α-cortolone | 5b20acortolone | HMDB0003128 | 516-42-7 | | 5β,20β-cortolone | 5b20bcortolone | NA | NA | | 6β-hydroxycortisone | 6OHE | NA | NA | | 5α-tetrahydrocorticosterone | 5aTHB | HMDB0000449 | 600-63-5 | | 5β-tetrahydrocorticosterone | 5bTHB | HMDB0000268 | 68-42-8 | | 17-deoxycortolone | 17-DO-cortolone | NA | NA | | **Glucocorticosteroid precursor** | | | | | Deoxycorticosterone | DOC | HMDB0000016 | 64-85-7 | | Cortexolone | S | HMDB0000015 | 152-58-9 | | 17-hydroxyprogesterone | 17OHP | HMDB0000374 | 68-96-2 | | **Glucocorticosteroid precursor metabolite** | | | | | Tetrahydrocortexolone | THS | HMDB0005972 | 68-60-0 | | Pregnantriol | PT | NA | 1098-45-9 | | 17-hydroxypregnanolone | 17HP | HMDB0000363 | 387-79-1 | | 5β-dihydrocortexolone | 5bDHS | NA | NA | | 5β-tetrahydrocortexolone | 5bTHS | NA | NA | | **Androgen** | | | | | Testosterone | T | HMDB0000234 | 58-22-0 | | Androsternedione | AED | HMDB0000053 | 63-05-8 | | **Androgen metabolite** | | | | | Androsterone | Andros | HMDB0000031 | 53-41-8 | | Etiocholanolone | Etio | HMDB0000490 | 53-42-9 | | Abbreviations: Human Metabolome Database (HMDB); Chemical Abstracts Service (CAS). | | | |   Table S7: **Information about the glucocorticosteroids, including the full metabolite name, the standard symbol, the identifier from the HMDB, and the CAS number.** |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| | LLOQ | Metabolite | | --- | --- | | 2.00 | 11OHAndros | | 0.50 | 17DOcortolone | | 2.00 | 17HP | | 0.50 | 20aDHE | | 0.25 | 20aDHF | | 0.50 | 20bDHE | | 0.50 | 20bDHF | | 2.50 | 5a20acortol | | 2.50 | 5a20bcortol | | 0.50 | 5aTHB | | 0.50 | 5aTHE | | 5.00 | 5aTHF | | 2.50 | 5b20acortol | | 5.00 | 5b20acortolone | | 2.50 | 5b20bcortol | | 5.00 | 5b20bcortolone | | 0.10 | 5bDHF | | 0.10 | 5bDHS | | 0.50 | 5bTHB | | 5.00 | 5bTHE | | 0.50 | 5bTHF | | 0.50 | 5bTHS | | 0.50 | 6OHE | | 0.50 | 6OHF | | 0.10 | A | | 0.10 | AED | | 0.50 | Andros | | 0.50 | E | | 0.50 | Etio | | 0.25 | F | | 2.00 | PT | | 0.10 | S | | 0.10 | T | | Abbreviations: lower limit of quantification (LLOQ). | |   Table S8: **Lower limits of quantification expressed in ng/ml for the glucocorticosteroids (HELIX subcohort; 2013-2016).** |

## Tables for main results

### Balancing weights

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| | Exposure | Unadjusted | Adjusted*a* | | --- | --- | --- | | **Phenols** | | | | etpa | 1,297 | 1,289 | | oxbe | 1,297 | 1,277 | | bupa | 1,297 | 1,276 | | prpa | 1,297 | 1,275 | | mepa | 1,297 | 1,266 | | trcs | 1,297 | 1,255 | | bpa | 1,297 | 1,137 | | **OP pesticide metabolites** | | | | detp | 1,297 | 1,222 | | dep | 1,297 | 1,222 | | dmtp | 1,297 | 1,219 | | dmp | 1,297 | 1,172 | | **Phthalate metabolites** | | | | oxominp | 1,297 | 1,199 | | ohminp | 1,297 | 1,172 | | mbzp | 1,297 | 1,113 | | mehp | 1,297 | 1,089 | | mep | 1,297 | 1,055 | | mnbp | 1,297 | 1,035 | | mehhp | 1,297 | 1,010 | | meohp | 1,297 | 1,001 | | mecpp | 1,297 | 980.0 | | mibp | 1,297 | 927.1 | | *a*Truncated weights. | | |   Table S9: **Effective sample size before and after balancing weights estimation (exposures: EDCs; outcome: HRT-SE) (HELIX subcohort; 2013-2016).** |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| | exposure | Unadjusted | Adjusted*a* | | --- | --- | --- | | **Phenols** | | | | oxbe | 976.0 | 960.1 | | prpa | 976.0 | 955.8 | | mepa | 976.0 | 953.8 | | bupa | 976.0 | 952.5 | | etpa | 976.0 | 951.7 | | trcs | 976.0 | 943.0 | | bpa | 976.0 | 855.7 | | **OP pesticide metabolites** | | | | detp | 976.0 | 922.4 | | dep | 976.0 | 921.5 | | dmtp | 976.0 | 907.3 | | dmp | 976.0 | 892.5 | | **Phthalate metabolites** | | | | ohminp | 976.0 | 878.3 | | oxominp | 976.0 | 874.0 | | mbzp | 976.0 | 827.7 | | mehp | 976.0 | 827.4 | | mep | 976.0 | 795.7 | | mehhp | 976.0 | 783.7 | | mecpp | 976.0 | 767.4 | | meohp | 976.0 | 761.5 | | mnbp | 976.0 | 745.9 | | mibp | 976.0 | 689.8 | | *a*Truncated weights. | | |   Table S10: **Effective sample size before and after balancing weights estimation (exposures: EDCs; outcomes: glucocorticosteroids) (HELIX subcohort; 2013-2016).** |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| | exposure | Unadjusted | Adjusted*a* | | --- | --- | --- | | cortisone production | 976.0 | 777.2 | | corticosterone production | 976.0 | 758.1 | | cortisol production | 976.0 | 751.6 | | *a*Truncated weights. | | |   Table S11: **Effective sample size before and after balancing weights estimation (exposures: glucocorticosteroids; outcome: HRT-SE) (HELIX subcohort; 2013-2016).** |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  | Median (IQR) | Range | | --- | --- | --- | | **Characteristic***a* | **N = 1,297***a* | **N = 1,297***a* | | mep | 0.93 (0.61, 1.27) | 0.28, 1.77 | | mibp | 0.91 (0.46, 1.38) | 0.05, 1.93 | | mnbp | 0.98 (0.59, 1.33) | 0.19, 1.74 | | mbzp | 0.98 (0.66, 1.28) | 0.34, 1.62 | | mehp | 0.98 (0.64, 1.27) | 0.31, 1.68 | | mehhp | 0.96 (0.54, 1.35) | 0.16, 1.75 | | meohp | 0.96 (0.52, 1.35) | 0.15, 1.78 | | mecpp | 0.95 (0.50, 1.34) | 0.14, 1.84 | | ohminp | 1.01 (0.74, 1.24) | 0.47, 1.50 | | oxominp | 1.01 (0.78, 1.20) | 0.52, 1.43 | | mepa | 1.01 (0.90, 1.13) | 0.74, 1.25 | | etpa | 1.01 (0.96, 1.07) | 0.88, 1.14 | | prpa | 1.01 (0.92, 1.12) | 0.80, 1.23 | | bpa | 0.99 (0.70, 1.27) | 0.38, 1.57 | | bupa | 1.01 (0.91, 1.11) | 0.81, 1.22 | | oxbe | 1.01 (0.92, 1.10) | 0.79, 1.21 | | trcs | 1.01 (0.87, 1.13) | 0.68, 1.28 | | dmp | 0.98 (0.73, 1.25) | 0.49, 1.51 | | dmtp | 1.00 (0.81, 1.20) | 0.59, 1.39 | | dep | 1.01 (0.81, 1.19) | 0.59, 1.38 | | detp | 0.99 (0.81, 1.18) | 0.61, 1.41 | | *a*Truncated weights. | | |   Table S12: **Summary statistics of the estimated balancing weights (exposures: EDCs; outcome: HRT-SE) (HELIX subcohort; 2013-2016).** |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  | Median (IQR) | Range | | --- | --- | --- | | **Characteristic***a* | **N = 976***a* | **N = 976***a* | | mep | 0.93 (0.60, 1.27) | 0.28, 1.74 | | mibp | 0.88 (0.43, 1.38) | 0.08, 1.98 | | mnbp | 0.97 (0.53, 1.36) | 0.14, 1.84 | | mbzp | 0.94 (0.68, 1.28) | 0.35, 1.69 | | mehp | 0.98 (0.64, 1.29) | 0.33, 1.63 | | mehhp | 0.98 (0.56, 1.35) | 0.21, 1.70 | | meohp | 0.98 (0.52, 1.35) | 0.18, 1.78 | | mecpp | 0.95 (0.55, 1.36) | 0.19, 1.77 | | ohminp | 1.00 (0.73, 1.25) | 0.46, 1.49 | | oxominp | 1.01 (0.71, 1.25) | 0.45, 1.52 | | mepa | 1.00 (0.90, 1.13) | 0.75, 1.26 | | etpa | 1.02 (0.90, 1.14) | 0.72, 1.24 | | prpa | 1.00 (0.92, 1.12) | 0.77, 1.26 | | bpa | 0.99 (0.70, 1.26) | 0.40, 1.58 | | bupa | 1.01 (0.89, 1.13) | 0.75, 1.27 | | oxbe | 1.01 (0.92, 1.10) | 0.78, 1.21 | | trcs | 1.01 (0.86, 1.13) | 0.69, 1.29 | | dmp | 0.99 (0.75, 1.23) | 0.51, 1.46 | | dmtp | 1.00 (0.79, 1.23) | 0.56, 1.41 | | dep | 0.99 (0.81, 1.19) | 0.63, 1.42 | | detp | 0.99 (0.82, 1.18) | 0.62, 1.41 | | *a*Truncated weights. | | |   Table S13: **Summary statistics of the estimated balancing weights (exposures: EDCs; outcomes: glucocorticosteroids) (HELIX subcohort; 2013-2016).** |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  | Median (IQR) | Range | | --- | --- | --- | | **Characteristic***a* | **N = 976***a* | **N = 976***a* | | cortisol\_production | 1.00 (0.54, 1.40) | 0.14, 1.80 | | cortisone\_production | 1.01 (0.58, 1.39) | 0.19, 1.73 | | corticosterone\_production | 0.98 (0.56, 1.39) | 0.16, 1.78 | | *a*Truncated weights. | | |   Table S14: **Summary statistics of the estimated balancing weights (exposures: glucocorticosteroids; outcome: HRT-SE) (HELIX subcohort; 2013-2016).** |

## Tables for other results

### Balancing weights for effect modification

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  | Median (IQR) | | Range | | | --- | --- | --- | --- | --- | | **Characteristic***a* | **females**, N = 587*a* | **males**, N = 710*a* | **females**, N = 587*a* | **males**, N = 710*a* | | mep | 0.96 (0.67, 1.26) | 0.93 (0.61, 1.30) | 0.31, 1.67 | 0.31, 1.67 | | mibp | 0.93 (0.51, 1.39) | 0.96 (0.52, 1.40) | 0.16, 1.85 | 0.16, 1.85 | | mnbp | 1.00 (0.62, 1.33) | 0.98 (0.59, 1.35) | 0.28, 1.68 | 0.28, 1.68 | | mbzp | 1.00 (0.71, 1.27) | 0.99 (0.69, 1.28) | 0.40, 1.57 | 0.40, 1.57 | | mehp | 1.02 (0.69, 1.27) | 0.98 (0.62, 1.32) | 0.33, 1.62 | 0.33, 1.62 | | mehhp | 1.01 (0.60, 1.29) | 0.95 (0.55, 1.36) | 0.26, 1.72 | 0.26, 1.72 | | meohp | 1.00 (0.63, 1.29) | 0.95 (0.53, 1.41) | 0.23, 1.74 | 0.23, 1.74 | | mecpp | 1.00 (0.59, 1.33) | 0.95 (0.50, 1.38) | 0.23, 1.76 | 0.23, 1.76 | | ohminp | 1.02 (0.78, 1.22) | 1.00 (0.76, 1.23) | 0.51, 1.46 | 0.51, 1.46 | | oxominp | 1.02 (0.84, 1.17) | 1.01 (0.77, 1.21) | 0.58, 1.39 | 0.58, 1.39 | | mepa | 1.02 (0.89, 1.15) | 1.02 (0.94, 1.11) | 0.76, 1.23 | 0.76, 1.23 | | etpa | 1.02 (0.96, 1.08) | 1.01 (0.97, 1.06) | 0.91, 1.12 | 0.91, 1.12 | | prpa | 1.02 (0.92, 1.13) | 1.02 (0.95, 1.10) | 0.82, 1.21 | 0.82, 1.21 | | bpa | 1.02 (0.73, 1.28) | 1.02 (0.74, 1.25) | 0.41, 1.50 | 0.41, 1.50 | | bupa | 1.02 (0.95, 1.10) | 1.01 (0.81, 1.19) | 0.67, 1.29 | 0.67, 1.29 | | oxbe | 1.03 (0.92, 1.12) | 1.02 (0.94, 1.09) | 0.80, 1.19 | 0.80, 1.19 | | trcs | 1.03 (0.92, 1.13) | 1.01 (0.89, 1.12) | 0.74, 1.25 | 0.74, 1.25 | | dmp | 0.99 (0.74, 1.25) | 1.00 (0.74, 1.25) | 0.53, 1.46 | 0.53, 1.46 | | dmtp | 1.00 (0.79, 1.22) | 1.01 (0.82, 1.20) | 0.58, 1.38 | 0.58, 1.38 | | dep | 1.01 (0.82, 1.19) | 1.02 (0.84, 1.17) | 0.64, 1.36 | 0.64, 1.36 | | detp | 1.00 (0.77, 1.22) | 1.01 (0.82, 1.20) | 0.57, 1.39 | 0.57, 1.39 | | *a*Truncated weights. | | | | |   Table S15: **Summary statistics of the estimated balancing weights for effect modification (exposures: EDCs; outcome: HRT-SE; modifier: sex) (HELIX subcohort; 2013-2016).** |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  | Median (IQR) | | Range | | | --- | --- | --- | --- | --- | | **Characteristic***a* | **females**, N = 434*a* | **males**, N = 542*a* | **females**, N = 434*a* | **males**, N = 542*a* | | mep | 0.99 (0.70, 1.24) | 0.95 (0.55, 1.30) | 0.31, 1.68 | 0.31, 1.68 | | mibp | 0.92 (0.46, 1.40) | 0.92 (0.54, 1.38) | 0.15, 1.85 | 0.15, 1.85 | | mnbp | 0.97 (0.51, 1.40) | 0.98 (0.56, 1.33) | 0.21, 1.78 | 0.21, 1.78 | | mbzp | 1.00 (0.70, 1.26) | 0.98 (0.66, 1.31) | 0.38, 1.58 | 0.38, 1.58 | | mehp | 1.01 (0.72, 1.28) | 0.99 (0.61, 1.34) | 0.37, 1.57 | 0.37, 1.57 | | mehhp | 1.02 (0.65, 1.31) | 1.00 (0.59, 1.34) | 0.30, 1.62 | 0.30, 1.62 | | meohp | 1.00 (0.62, 1.31) | 1.01 (0.50, 1.41) | 0.24, 1.68 | 0.24, 1.68 | | mecpp | 0.98 (0.62, 1.32) | 0.99 (0.53, 1.39) | 0.29, 1.67 | 0.29, 1.67 | | ohminp | 1.00 (0.73, 1.26) | 1.00 (0.77, 1.24) | 0.49, 1.45 | 0.49, 1.45 | | oxominp | 1.03 (0.73, 1.27) | 1.02 (0.77, 1.23) | 0.48, 1.45 | 0.48, 1.45 | | mepa | 1.01 (0.88, 1.17) | 1.03 (0.94, 1.11) | 0.73, 1.26 | 0.73, 1.26 | | etpa | 1.04 (0.92, 1.12) | 1.02 (0.92, 1.12) | 0.78, 1.22 | 0.78, 1.22 | | prpa | 1.03 (0.87, 1.16) | 1.02 (0.96, 1.10) | 0.74, 1.24 | 0.74, 1.24 | | bpa | 1.00 (0.71, 1.28) | 1.01 (0.75, 1.24) | 0.44, 1.52 | 0.44, 1.52 | | bupa | 1.02 (0.95, 1.11) | 1.01 (0.80, 1.19) | 0.64, 1.30 | 0.64, 1.30 | | oxbe | 1.03 (0.86, 1.16) | 1.02 (0.95, 1.09) | 0.76, 1.23 | 0.76, 1.23 | | trcs | 1.03 (0.92, 1.13) | 1.01 (0.88, 1.14) | 0.73, 1.25 | 0.73, 1.25 | | dmp | 0.98 (0.76, 1.23) | 1.01 (0.75, 1.21) | 0.57, 1.45 | 0.57, 1.45 | | dmtp | 1.03 (0.78, 1.22) | 1.01 (0.79, 1.23) | 0.56, 1.40 | 0.56, 1.40 | | dep | 1.01 (0.85, 1.16) | 1.00 (0.84, 1.19) | 0.67, 1.36 | 0.67, 1.36 | | detp | 1.00 (0.77, 1.23) | 1.00 (0.86, 1.17) | 0.57, 1.40 | 0.57, 1.40 | | *a*Truncated weights. | | | | |   Table S16: **Summary statistics of the estimated balancing weights for effect modification (exposures: EDCs; outcomes: glucocorticosteroids; modifier: sex) (HELIX subcohort; 2013-2016).** |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  | Median (IQR) | | Range | | | --- | --- | --- | --- | --- | | **Characteristic***a* | **females**, N = 434*a* | **males**, N = 542*a* | **females**, N = 434*a* | **males**, N = 542*a* | | cortisol\_production | 0.98 (0.57, 1.40) | 1.02 (0.59, 1.34) | 0.23, 1.71 | 0.23, 1.71 | | cortisone\_production | 1.00 (0.60, 1.40) | 1.00 (0.60, 1.38) | 0.27, 1.69 | 0.27, 1.69 | | corticosterone\_production | 1.01 (0.61, 1.39) | 1.03 (0.56, 1.37) | 0.22, 1.70 | 0.22, 1.70 | | *a*Truncated weights. | | | | |   Table S17: **Summary statistics of the estimated balancing weights for effect modification (exposures: glucocorticosteroids; outcome: HRT-SE; modifier: sex) (HELIX subcohort; 2013-2016).** |

# Supplementary figures

## Figures for descriptive data

### Study populations

|  |
| --- |
| Figure S1: Flowchart describing thew sample size for each research question. |

### Description of endocrine disruptors

|  |
| --- |
| Figure S2: **Measurement classification of EDCs, by cohort (HELIX subcohort; 2013-2016).** Coding: 1, quantifiable; 2, <LOD; 3, interference or out of range; 4. not analysed. |

### Description of glucocorticosteroids

|  |
| --- |
| Figure S3: **Measurement classification of the glucocorticosteroids, by cohort (HELIX subcohort; 2013-2016).** Coding: 1, quantifiable; 2, <LOQ; 3, interference or out of range; 4, not detected. |

## Figures for other results

### Marginal contrasts for effect modification

|  |
| --- |
| Figure S4: **Marginal contrasts for effect modification by sex of a decrease from the 90th to the 10th percentile of the EDCs on HRT-SE expressed in ms (HELIX subcohort; 2013-2016).** Circles and triangles indicate effect estimates. Solid lines indicate the CI. |

|  |
| --- |
| Figure S5: **Marginal contrasts for effect modification by sex of a decrease from the 90th to the 10th percentile of the EDCs on the glucocorticosteroids expressed in ng/ml (HELIX subcohort; 2013-2016).** Circles and triangles indicate effect estimates. Solid lines indicate the CI. |

|  |
| --- |
| Figure S6: **Marginal contrasts for effect modification by sex of a decrease from the 90th to the 10th percentile of the glucocorticosteroids on HRT-SE expressed in ms (HELIX subcohort; 2013-2016).** Circles and triangles indicate effect estimates. Solid lines indicate the CI. |